{"gene":"BRCA1","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1994,"finding":"BRCA1 was positionally cloned on chromosome 17q21, encoding a predicted 1863-amino-acid protein with a zinc finger domain in its amino-terminal region; probable predisposing mutations (frameshift, nonsense, missense, regulatory) were identified in familial breast/ovarian cancer kindreds.","method":"Positional cloning, mutation sequencing, linkage analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — original positional cloning with mutation identification, foundational discovery paper with >5000 citations","pmids":["7545954"],"is_preprint":false},{"year":1990,"finding":"A susceptibility locus for early-onset familial breast cancer was mapped to chromosome 17q21 by linkage analysis, establishing the chromosomal location of BRCA1.","method":"Genetic linkage analysis (LOD score analysis of RFLP markers)","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — genetic mapping with high LOD score, foundational discovery replicated across families","pmids":["2270482"],"is_preprint":false},{"year":1997,"finding":"BRCA1 colocalizes with RAD51 in discrete nuclear foci during S phase of the cell cycle, co-immunoprecipitates with RAD51, and BRCA1 residues 758–1064 alone form RAD51-containing complexes in vitro; both proteins associate with synaptonemal complexes in meiotic cells, suggesting a functional interaction in recombination and genome integrity control.","method":"Co-immunoprecipitation, in vitro binding assay, immunofluorescence colocalization, meiotic chromosome spreads","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus in vitro domain mapping, replicated in mitotic and meiotic contexts","pmids":["9008167"],"is_preprint":false},{"year":1997,"finding":"BRCA1 localizes to discrete S-phase nuclear foci that disperse upon DNA damage (UV, gamma-irradiation, mitomycin C, hydroxyurea); dispersal is accompanied by DNA damage-induced hyperphosphorylation of BRCA1 and redistribution of BRCA1/BARD1/RAD51 complexes to PCNA-positive replication structures, implicating BRCA1-containing complexes in a replication checkpoint response.","method":"Immunofluorescence, cell fractionation, Western blot phosphorylation shift analysis, co-immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, dynamic phosphorylation and relocalization directly linked to DNA damage response","pmids":["9267023"],"is_preprint":false},{"year":1999,"finding":"ATM kinase is required for BRCA1 phosphorylation in response to ionizing radiation; ATM resides in a complex with BRCA1 and phosphorylates BRCA1 in vivo and in vitro at serine-glutamine clusters; a BRCA1 mutant lacking two ATM phosphorylation sites fails to rescue radiation hypersensitivity of BRCA1-deficient cells.","method":"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, complementation of radiation hypersensitivity","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus mutagenesis rescue experiment, functionally validated","pmids":["10550055"],"is_preprint":false},{"year":1999,"finding":"BRCA1 RING finger domain mediates E2-dependent ubiquitination; mutations of metal-coordinating residues in the RING finger abolish ubiquitination activity, establishing BRCA1 as a RING-type E3 ubiquitin ligase.","method":"In vitro ubiquitination assay, mutagenesis of RING finger zinc-coordinating residues, chelation of zinc","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro ubiquitination with mutagenesis controls","pmids":["10500182"],"is_preprint":false},{"year":1999,"finding":"Brca1-deficient mouse embryonic stem cells have impaired repair of chromosomal double-strand breaks by homologous recombination, with altered frequencies of homologous versus nonhomologous DNA integration, demonstrating a caretaker role for BRCA1 in promoting homologous recombination.","method":"Gene targeting, DSB repair frequency assay in ES cells, Southern blotting","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined molecular phenotype in homologous recombination assay","pmids":["10549283"],"is_preprint":false},{"year":2000,"finding":"BRCA1 associates with a large nuclear surveillance complex (BASC) containing MSH2, MSH6, MLH1, ATM, BLM, RAD50-MRE11-NBS1, and RFC; BRCA1, BLM, and RAD50-MRE11-NBS1 colocalize to nuclear foci containing PCNA after agents that block DNA synthesis, placing BRCA1 as a coordinator of multiple DNA repair and replication activities.","method":"Immunoprecipitation-mass spectrometry, co-immunoprecipitation, immunofluorescence colocalization","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — mass spectrometry-based complex identification plus co-IP and colocalization, widely replicated","pmids":["10783165"],"is_preprint":false},{"year":2000,"finding":"ATR kinase phosphorylates BRCA1 on six Ser/Thr residues including Ser1423 in vitro; kinase-inactive ATR suppresses Ser1423 phosphorylation after HU or UV treatment; ATR forms nuclear foci overlapping BRCA1 foci at stalled replication forks, demonstrating ATR directly phosphorylates BRCA1 in response to DNA damage or replication stress.","method":"In vitro kinase assay, dominant-negative ATR expression, immunofluorescence colocalization, phospho-specific antibodies","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus dominant-negative rescue experiment with phospho-site mapping","pmids":["11114888"],"is_preprint":false},{"year":2001,"finding":"FANCD2, activated by monoubiquitination through a nuclear FA complex (FANCA/FANCC/FANCF/FANCG), colocalizes with BRCA1 in ionizing radiation-induced nuclear foci and on synaptonemal complexes, linking the Fanconi anemia pathway to the BRCA1 DNA repair machinery.","method":"Co-immunoprecipitation, immunofluorescence colocalization, Western blot (monoubiquitination shift), cell fractionation","journal":"Molecular Cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP and colocalization in multiple contexts, widely replicated","pmids":["11239454"],"is_preprint":false},{"year":1998,"finding":"BRCA1 physically associates with p53 in vitro and in vivo, mapping to BRCA1 aa 224–500 and the p53 C-terminal domain; BRCA1 stimulates p53-dependent transcription from p21WAF1/CIP1 and bax promoters; tumor-derived BRCA1 mutants are defective in p53 co-activation; BRCA1 and p53 cooperatively induce apoptosis.","method":"Co-immunoprecipitation, GST pulldown, transient transfection transcriptional reporter assay, apoptosis assay, domain mapping","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo binding with domain mapping plus functional transcriptional assays","pmids":["9582019"],"is_preprint":false},{"year":2002,"finding":"BRCA1 colocalizes with markers of the inactive X chromosome and associates with XIST RNA (detected by ChIP); reconstitution of BRCA1-deficient cells with wild-type BRCA1 restores focal XIST RNA staining; inhibiting BRCA1 synthesis in a reporter line leads to increased expression of a silenced Xi-located GFP transgene, demonstrating BRCA1 supports XIST RNA concentration and inactive X chromosome maintenance.","method":"Immunofluorescence colocalization, chromatin immunoprecipitation, reconstitution assay, GFP reporter gene expression assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus functional reconstitution and reporter gene assay","pmids":["12419249"],"is_preprint":false},{"year":2004,"finding":"C. elegans BRC-1 (BRCA1 ortholog) and BRD-1 (BARD1 ortholog) are required for DNA repair; their depletion causes elevated p53-dependent germ cell death, impaired progeny survival after irradiation, and chromosome fragmentation, functionally conserving the BRCA1/BARD1 repair pathway.","method":"RNAi depletion, irradiation survival assay, genetic epistasis, cytological analysis","journal":"Current Biology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function in model organism with defined DNA repair phenotype, consistent with mammalian function","pmids":["14711411"],"is_preprint":false},{"year":2005,"finding":"BRCA1 interacts and colocalizes with topoisomerase IIα in S-phase cells; BRCA1-deficient cells show lagging chromosomes and defective DNA decatenation in vitro; topoisomerase IIα is ubiquitinated in a BRCA1-dependent manner, and this ubiquitination correlates with higher decatenation activity, revealing a BRCA1 role in DNA decatenation and chromosome segregation.","method":"Co-immunoprecipitation, immunofluorescence, in vitro decatenation assay, chromosome analysis, ubiquitination assay","journal":"Nature Structural & Molecular Biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro activity assay plus Co-IP, ubiquitination, and functional genetic analysis","pmids":["15965487"],"is_preprint":false},{"year":2007,"finding":"CCDC98 (Abraxas) mediates BRCA1 association with RAP80 and is required for DNA damage-induced BRCA1 nuclear foci formation and BRCA1-dependent G2/M checkpoint activation.","method":"Co-immunoprecipitation, immunofluorescence, siRNA knockdown, checkpoint assay","journal":"Nature Structural & Molecular Biology","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus functional checkpoint assay with KD","pmids":["17643121"],"is_preprint":false},{"year":2007,"finding":"RNF8 ubiquitylates histone H2A and H2AX at DNA double-strand breaks via its RING domain after phospho-dependent binding to MDC1 through its FHA domain; this ubiquitylation is required for accumulation of BRCA1 (and 53BP1) at DSB sites; RNF8 depletion impairs G2/M checkpoint and increases IR sensitivity.","method":"Co-immunoprecipitation, in vitro ubiquitination, siRNA knockdown, immunofluorescence, checkpoint assay, X-ray crystallography of FHA domain","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus in vitro ubiquitination and functional genetic analysis","pmids":["18001824","18001825"],"is_preprint":false},{"year":2008,"finding":"BRCA1 binds the SIRT1 promoter and increases SIRT1 expression; SIRT1 in turn inhibits Survivin by altering histone H3 epigenetic modifications; absence of SIRT1 blocks BRCA1-mediated Survivin regulation; demonstrated in Brca1-mutant mouse mammary tumors and in vitro.","method":"Chromatin immunoprecipitation, promoter reporter assay, siRNA knockdown, Western blot, mouse tumor model","journal":"Molecular Cell","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and functional siRNA rescue, single lab","pmids":["18851829"],"is_preprint":false},{"year":2009,"finding":"BAP1 (ubiquitin C-terminal hydrolase) interacts with the BARD1 RING domain (residues 182–365 of BAP1) via surface plasmon resonance; BAP1 interferes with BRCA1/BARD1 heterodimerization, inhibiting BRCA1/BARD1 autoubiquitination and NPM1/B23 ubiquitination; a catalytically inactive BAP1 mutant (C91S) also inhibits ubiquitination, indicating a second steric mechanism; BAP1 depletion causes IR hypersensitivity and S-phase retardation.","method":"Surface plasmon resonance (BIAcore), in vitro ubiquitination assay, catalytic mutant analysis, shRNA knockdown, cell cycle assay","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 1 — biophysical binding assay plus in vitro ubiquitination with mutagenesis and functional cellular phenotype","pmids":["19117993"],"is_preprint":false},{"year":2009,"finding":"BRCA1 overexpression reduces acetylated ER-α levels and increases mono-ubiquitinated ER-α; a BRCA1 ubiquitin ligase-dead mutant (I26A) neither ubiquitinates ER-α nor represses its activity; in vitro, BRCA1 inhibits p300-mediated acetylation of ER-α; a cancer-associated BRCA1 mutant (C61G) lacks this activity, linking BRCA1 E3 ligase activity to regulation of ER-α via competing acetylation/ubiquitination.","method":"In vitro ubiquitination assay, in vitro acetylation assay, siRNA knockdown, Western blot, transient transfection reporter assay","journal":"Molecular Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assays plus mutagenesis and cellular functional assay","pmids":["19887647"],"is_preprint":false},{"year":2009,"finding":"MERIT40 is a component of the RAP80/CCDC98-containing BRCA1-A complex; it interacts directly with BRE/BRCC45 to maintain complex stability; MERIT40 is required for BRCA1 retention at DNA breaks and for checkpoint function.","method":"Co-immunoprecipitation, siRNA knockdown, immunofluorescence foci assay, checkpoint assay, protein stability assay","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with functional siRNA knockdown and defined checkpoint phenotype","pmids":["19261748"],"is_preprint":false},{"year":2010,"finding":"BRCA1 deficiency leads to global DNA hypomethylation and loss of genomic imprinting; BRCA1 binds the DNMT1 promoter through a potential OCT1 site and maintains transcriptional activity of DNMT1; demonstrated in BRCA1-mutant mouse models and human clinical samples.","method":"Chromatin immunoprecipitation, promoter assay, bisulfite sequencing, mouse knockout model, Western blot","journal":"Cell Research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and promoter analysis with in vivo mouse model, single lab","pmids":["20820192"],"is_preprint":false},{"year":2010,"finding":"BRCA1 assembles with E2F-1 and RB to form a repressive transcriptional complex at the BRCA1 promoter; genotoxic stress disrupts this complex, displacing BRCA1 and upregulating BRCA1 transcription, defining an autoregulatory loop; demonstrated by tandem ChIP.","method":"Tandem chromatin immunoprecipitation (Re-ChIP), siRNA knockdown, promoter reporter assay, Western blot","journal":"Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — tandem ChIP with functional siRNA analysis, single lab","pmids":["20068145"],"is_preprint":false},{"year":2010,"finding":"BRCA1 expression is controlled by a CtBP-containing co-repressor complex regulating HDAC1 and histone acetylation at the BRCA1 promoter; eviction of CtBP by estrogen, siRNA, or elevated NAD+/NADH leads to HDAC1 dismissal and increased BRCA1 transcription, revealing a metabolic switch coupling caloric intake to tumor suppressor expression.","method":"Chromatin immunoprecipitation, siRNA knockdown, NAD+/NADH metabolic manipulation, HDAC inhibitor treatment, promoter reporter assay","journal":"Nature Structural & Molecular Biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP with mechanistic metabolic manipulation, single lab","pmids":["21102443"],"is_preprint":false},{"year":2012,"finding":"Loss of 53BP1 rescues the growth arrest, checkpoint defects, and partially rescues the homologous recombination defect and DNA damage hypersensitivity of Brca1-deleted cells; 53BP1 acts downstream of ATM to sustain the checkpoint response in BRCA1-deficient cells; this rescue is specific to BRCA1 (not BRCA2) deficiency, defining an epistatic relationship between BRCA1 and the 53BP1 pathway in DNA repair pathway choice.","method":"Conditional knockout mouse cells, siRNA knockdown, HR assay, checkpoint assay, drug hypersensitivity assay","journal":"Nature Structural & Molecular Biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in clean KO cells with multiple orthogonal phenotypic readouts","pmids":["20453858"],"is_preprint":false},{"year":2012,"finding":"FANCD2 and BRCA1 are required for protection of stalled replication forks from degradation in a repair-independent manner; this fork protection is epistatic with RAD51 stabilization, linking FA genes, RAD51, and BRCA1/2 in a unified fork protection pathway.","method":"DNA fiber assay (replication fork degradation), siRNA knockdown, RAD51 overexpression rescue, genetic epistasis","journal":"Cancer Cell","confidence":"High","confidence_rationale":"Tier 2 — DNA fiber assay with epistasis and rescue experiments","pmids":["22789542"],"is_preprint":false},{"year":2013,"finding":"RIF1 translocates to DNA damage sites via ATM-dependent 53BP1 phosphorylation and counteracts BRCA1-mediated DNA end resection; loss of RIF1 rescues end resection and checkpoint activation in BRCA1-depleted cells; BRCA1 antagonizes RIF1 accumulation at damage sites in S/G2, while RIF1 inhibits BRCA1 recruitment in G1; RIF1 also promotes BLM chromatin loading independently of 53BP1.","method":"siRNA knockdown, immunofluorescence foci assay, end resection assay, checkpoint assay, cell cycle fractionation","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — epistasis analysis with multiple KDs and cell-cycle-specific mechanistic dissection","pmids":["23486525"],"is_preprint":false},{"year":2004,"finding":"Casein kinase 2 beta-subunit binds BRCA1 C-terminal region (identified by yeast two-hybrid and confirmed in Sf9 cells); CK2 phosphorylates BRCA1 in vitro, requiring Ser1572; the cancer-associated missense mutant M1775R shows weaker CK2 association.","method":"Yeast two-hybrid, in vitro kinase assay, site-directed mutagenesis, Sf9 cell expression","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 1–3 — in vitro kinase assay with mutagenesis but limited cellular validation","pmids":["10403822"],"is_preprint":false},{"year":2004,"finding":"The BRCA1 RING and BRCT domains cooperate to target BRCA1 to ionizing radiation-induced nuclear foci; cancer-specific mutations in the BRCT domain abolish foci recruitment; neither domain alone is sufficient, but their combination restores foci targeting, co-localizing with MDC1.","method":"YFP-BRCA1 domain mapping in MCF-7 cells, immunofluorescence after ionizing radiation, dominant-negative competition","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 — domain-deletion live-cell imaging with functional competition assay, single lab","pmids":["15569676"],"is_preprint":false},{"year":2004,"finding":"BRCA1-IRIS, a distinct BRCA1 locus product encoded from codon 1 through intron 11, is exclusively chromatin-associated, does not interact with BARD1 in vivo or in vitro, co-immunoprecipitates with DNA replication-licensing proteins, and suppression of BRCA1-IRIS impairs DNA replication initiation while overexpression stimulates it. [Note: classified as a distinct protein isoform/alt product from the BRCA1 locus; KEEP as it describes a direct protein product and its mechanistic distinction from p220 BRCA1 is itself a mechanistic finding about the locus.]","method":"Co-immunoprecipitation, immunostaining, BRCA1-IRIS siRNA knockdown, DNA replication assay, chromatin fractionation","journal":"Nature Cell Biology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with functional replication assay and siRNA knockdown, single lab","pmids":["15448696"],"is_preprint":false},{"year":2003,"finding":"BRCA1 associates specifically with hyperphosphorylated, elongating RNA polymerase II (pol IIO) rather than the hypophosphorylated initiating form (pol IIA); BRCA1-RNA pol II complexes are functional in transcriptional run-off assays; interaction is disrupted by DNA-damaging agents, placing BRCA1 in position to link processive transcription with DNA repair surveillance.","method":"Subcellular fractionation, co-immunoprecipitation, in vitro transcriptional run-off assay, phospho-specific antibodies","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with in vitro functional assay, single lab","pmids":["14506230"],"is_preprint":false},{"year":2004,"finding":"Ionizing radiation stimulates BRCA1 nuclear export in a dose-dependent and CRM1-dependent manner; this export requires wild-type p53 function (abrogated by HPV E6); BRCA1 localization varies across the cell cycle and is regulated by p53-dependent mechanisms in addition to kinase-dependent phosphorylation.","method":"Immunohistochemical staining, subcellular fractionation and Western blot, CRM1 inhibitor (leptomycin B), inducible p53 system, cell cycle fractionation","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods with genetic p53 requirement established, single lab","pmids":["15087457"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structure of BRCA1-BARD1 on a nucleosome reveals that BARD1 ankyrin repeat and tandem BRCT domains adopt a compact fold binding nucleosomal histones, DNA, and monoubiquitin on H2A K13/K15 (DSB-specific marks); RING domains orient an E2 enzyme atop the nucleosome for ubiquitin transfer to H2A/H2AX C-terminal tails; recognition of N-terminal H2A monoubiquitin blocks polyubiquitin chain formation and cooperatively promotes C-terminal H2A ubiquitylation, explaining BRCA1-BARD1 chromatin recruitment and specificity.","method":"Cryo-electron microscopy structure determination, biochemical ubiquitination assay, mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with biochemical validation and mutagenesis, single high-quality paper with orthogonal methods","pmids":["34321665"],"is_preprint":false},{"year":2021,"finding":"SIRT2 deacetylase complexes with BRCA1-BARD1 and deacetylates conserved lysines in the BARD1 RING domain at the BRCA1-BARD1 interface, promoting heterodimerization, mutual stability, nuclear retention, and localization to DNA damage sites, thereby facilitating homologous recombination.","method":"Co-immunoprecipitation, in vitro deacetylation assay, siRNA knockdown, nuclear fractionation, HR assay, immunofluorescence","journal":"Cell Reports","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro enzymatic assay with Co-IP, subcellular fractionation, and functional HR assay","pmids":["33789098"],"is_preprint":false},{"year":2024,"finding":"BRCA1 promotes transcription of VDAC3 and GPX4; BRCA1 deficiency blocks VDAC3-dependent erastin-induced ferroptosis but sensitizes cells to GPX4 inhibitor-induced ferroptosis; NCOA4-mediated ferritinophagy and defective GPX4 induction synergize with PARP inhibition to induce ferroptosis in BRCA1-deficient cancers, revealing a dual regulatory role for BRCA1 in ferroptosis.","method":"siRNA/CRISPR knockdown, transcriptional reporter/ChIP, ferroptosis assays (cell viability, lipid peroxidation), xenograft tumor models, patient-derived xenograft","journal":"Cancer Discovery","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP with functional loss-of-function assays and in vivo xenograft, single lab","pmids":["38552003"],"is_preprint":false},{"year":2006,"finding":"Loss of Brca1 in mouse T-cells results in telomere dysfunction including loss of telomere repeats and defective telomere capping; Brca1 synergizes with p53 deficiency to promote tumorigenesis with clonal chromosomal translocations arising from telomere dysfunction.","method":"Conditional knockout mouse model, telomere FISH, karyotyping, tumor incidence analysis","journal":"Human Molecular Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — clean conditional KO with direct cytological telomere analysis and functional tumor phenotype","pmids":["16446310"],"is_preprint":false},{"year":2014,"finding":"Neural progenitor-specific deletion of BRCA1 in developing mouse brain causes severe agenesis of neocortex, hippocampus, cerebellum, and olfactory bulbs primarily through excess p53-dependent apoptosis; centrosomal/cell polarity phenotypes are not rescued by p53 co-deletion but are partially rescued by ATM co-deletion, demonstrating distinct apoptotic and centrosomal functions of BRCA1 in neural progenitors.","method":"Conditional knockout mouse genetics, histology, p53 and ATM double-KO epistasis, immunofluorescence","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with double-KO epistasis to dissect distinct functions","pmids":["24639535"],"is_preprint":false}],"current_model":"BRCA1 is a multifunctional nuclear tumor suppressor that acts as a RING-type E3 ubiquitin ligase (heterodimerizing with BARD1, with specificity for nucleosomal H2A determined by cryo-EM structure), promotes homologous recombination repair of DNA double-strand breaks (via RAD51 interaction and DNA end resection antagonizing 53BP1/RIF1), is phosphorylated by ATM (at SQ clusters) and ATR (at Ser1423) after DNA damage, assembles into large surveillance complexes (BASC, BRCA1-A) to coordinate repair machinery, protects stalled replication forks from degradation, regulates transcription (co-activating p53 targets, interacting with RNA pol II, autoregulating its own promoter), maintains inactive X-chromosome XIST RNA localization, controls centrosome duplication, regulates ferroptosis via VDAC3/GPX4 transcription, and interfaces with the Fanconi anemia pathway through FANCD2 colocalization."},"narrative":{"teleology":[{"year":1990,"claim":"Before the gene was cloned, linkage analysis established that a breast cancer susceptibility locus resided on chromosome 17q21, defining the target for positional cloning.","evidence":"Genetic linkage (LOD score) with RFLP markers in early-onset breast cancer families","pmids":["2270482"],"confidence":"High","gaps":["Gene identity unknown","No protein or functional information"]},{"year":1994,"claim":"Positional cloning identified BRCA1 as an 1863-amino-acid protein harboring a zinc-finger domain, with frameshift, nonsense, and missense mutations segregating in familial breast/ovarian cancer kindreds, establishing it as a tumor suppressor gene.","evidence":"Positional cloning with mutation sequencing and linkage analysis in affected families","pmids":["7545954"],"confidence":"High","gaps":["Biochemical activity unknown","Cellular function uncharacterized","No structural data"]},{"year":1997,"claim":"Demonstration that BRCA1 colocalizes and physically interacts with RAD51 in S-phase nuclear foci and on meiotic chromosomes, and that DNA damage triggers BRCA1 hyperphosphorylation and redistribution to PCNA-positive replication structures, established BRCA1 as a participant in DNA repair and replication checkpoint responses.","evidence":"Co-immunoprecipitation, in vitro binding, immunofluorescence, phosphorylation shift assays in mitotic and meiotic cells","pmids":["9008167","9267023"],"confidence":"High","gaps":["Enzymatic activity of BRCA1 unknown","Upstream kinase not identified","Mechanism of RAD51 cooperation unclear"]},{"year":1998,"claim":"BRCA1 was shown to bind p53 and co-activate p53-dependent transcription from p21 and bax promoters, with cancer-derived mutants defective in this activity, revealing a transcriptional co-activator function linked to tumor suppression.","evidence":"Co-IP, GST pulldown, transcriptional reporter assays, domain mapping","pmids":["9582019"],"confidence":"High","gaps":["Direct versus indirect transcriptional mechanism unclear","Genome-wide transcriptional targets unknown"]},{"year":1999,"claim":"Three key mechanistic advances established BRCA1's enzymatic identity and upstream regulation: the RING finger was shown to confer E2-dependent E3 ubiquitin ligase activity; ATM was identified as the kinase that phosphorylates BRCA1 at SQ clusters after ionizing radiation (required for radiation resistance); and Brca1-null ES cells were proven defective in homologous recombination repair of DSBs.","evidence":"In vitro ubiquitination with RING mutagenesis; in vitro kinase assay with ATM plus complementation rescue; DSB repair frequency assay in Brca1-knockout ES cells","pmids":["10500182","10550055","10549283"],"confidence":"High","gaps":["Physiological ubiquitin substrates unidentified","How E3 activity relates to HR unclear","BARD1 contribution to E3 activity not yet dissected"]},{"year":2000,"claim":"BRCA1 was found to organize a large nuclear surveillance complex (BASC) containing mismatch repair, BLM helicase, MRN complex, ATM, and RFC, and ATR was identified as a second damage-responsive kinase directly phosphorylating BRCA1 at Ser1423, positioning BRCA1 as a central scaffold integrating multiple repair and checkpoint pathways.","evidence":"IP-mass spectrometry, co-IP, colocalization; in vitro kinase assay with dominant-negative ATR and phospho-specific antibodies","pmids":["10783165","11114888"],"confidence":"High","gaps":["Stoichiometry and dynamics of BASC unknown","Which ATR phosphosites are functionally essential beyond Ser1423 unclear"]},{"year":2001,"claim":"Monoubiquitinated FANCD2 was shown to colocalize with BRCA1 at damage-induced foci, linking the Fanconi anemia pathway to BRCA1-dependent DNA repair and establishing a functional convergence of these tumor suppressor networks.","evidence":"Co-IP, immunofluorescence colocalization, monoubiquitination shift assay","pmids":["11239454"],"confidence":"High","gaps":["Direct physical interaction between BRCA1 and FANCD2 not demonstrated at that time","Mechanistic basis of functional epistasis unclear"]},{"year":2002,"claim":"BRCA1 was found to colocalize with the inactive X chromosome, associate with XIST RNA, and be required for maintenance of XIST RNA concentration and X-linked gene silencing, revealing an unexpected role in epigenetic chromosome regulation beyond DNA repair.","evidence":"ChIP for XIST RNA association, immunofluorescence, reconstitution in BRCA1-deficient cells, GFP reporter assay","pmids":["12419249"],"confidence":"High","gaps":["Whether XIST association is direct RNA binding or indirect via chromatin","Relevance to tumor suppression not established"]},{"year":2004,"claim":"Multiple studies expanded BRCA1's functional repertoire: BRCA1 ubiquitinates topoisomerase IIα to stimulate decatenation activity and ensure chromosome segregation; RING and BRCT domains cooperate for damage-induced foci recruitment; and CRM1-dependent nuclear export of BRCA1 after irradiation requires p53.","evidence":"Co-IP/ubiquitination/decatenation assays; YFP domain mapping in irradiated cells; subcellular fractionation with CRM1 inhibitor and p53 perturbation","pmids":["15965487","15569676","15087457"],"confidence":"High","gaps":["In vivo relevance of topoisomerase IIα ubiquitination for tumor suppression","Structural basis of RING-BRCT cooperation unknown"]},{"year":2007,"claim":"The upstream chromatin signaling cascade recruiting BRCA1 to DSBs was defined: RNF8 ubiquitylates H2A/H2AX at breaks via MDC1, and the adaptor Abraxas/CCDC98 bridges RAP80 to BRCA1 for focal accumulation and G2/M checkpoint activation, establishing the BRCA1-A complex architecture.","evidence":"Co-IP, in vitro ubiquitination, siRNA knockdown, checkpoint assays, X-ray crystallography of RNF8 FHA domain","pmids":["17643121","18001824"],"confidence":"High","gaps":["How BRCA1-A complex is disassembled after repair","Relative contributions of multiple BRCA1 subcomplexes (A, B, C) to repair not resolved"]},{"year":2009,"claim":"BAP1 deubiquitinase was shown to bind the BARD1 RING domain via SPR, competing with BRCA1 heterodimerization and inhibiting BRCA1/BARD1 autoubiquitination through both enzymatic and steric mechanisms; separately, BRCA1 E3 ligase activity was shown to mono-ubiquitinate ERα, blocking p300-mediated acetylation and repressing ERα transcriptional activity.","evidence":"Surface plasmon resonance, in vitro ubiquitination/acetylation assays, catalytic mutant analysis, shRNA knockdown","pmids":["19117993","19887647"],"confidence":"High","gaps":["Physiological regulation of BAP1–BARD1 competition in vivo","Whether ERα ubiquitination occurs genome-wide or at specific loci"]},{"year":2010,"claim":"BRCA1 was shown to regulate its own promoter through an E2F1/RB-containing repressive complex (disrupted by genotoxic stress) and to maintain DNMT1 expression and genomic DNA methylation, extending its transcriptional regulatory roles to epigenomic maintenance and autoregulation.","evidence":"Tandem ChIP (Re-ChIP), promoter reporter assays, bisulfite sequencing in Brca1-mutant mouse models","pmids":["20068145","20820192"],"confidence":"Medium","gaps":["In vivo significance of autoregulatory loop for tumor suppression unclear","DNMT1 regulation not validated beyond one lab"]},{"year":2012,"claim":"Two genetic epistasis studies resolved how BRCA1 governs DSB repair pathway choice and fork protection: loss of 53BP1 rescued HR and checkpoint defects of Brca1-deleted cells (but not Brca2-deleted), defining BRCA1 as antagonizing 53BP1-mediated end protection; separately, BRCA1 and FANCD2 were shown to protect stalled replication forks from degradation in an epistatic pathway with RAD51.","evidence":"Conditional knockout epistasis in mouse cells with HR/checkpoint/drug sensitivity assays; DNA fiber assay with siRNA knockdown and RAD51 rescue","pmids":["20453858","22789542"],"confidence":"High","gaps":["Molecular mechanism by which BRCA1 displaces 53BP1 not known at this time","Whether fork protection and HR functions are separable"]},{"year":2013,"claim":"RIF1 was identified as the 53BP1 effector antagonized by BRCA1: RIF1 blocks end resection in G1, and BRCA1 counteracts RIF1 accumulation at DSBs in S/G2, providing a cell-cycle-dependent mechanism for repair pathway choice between NHEJ and HR.","evidence":"siRNA epistasis, immunofluorescence foci, end resection assay, cell cycle fractionation","pmids":["23486525"],"confidence":"High","gaps":["Direct biochemical mechanism of RIF1 displacement by BRCA1 not resolved","How BRCA1 senses cell cycle phase at individual DSBs unclear"]},{"year":2014,"claim":"Neural progenitor-specific Brca1 deletion caused severe brain agenesis through p53-dependent apoptosis, while centrosomal/polarity defects were ATM-dependent but p53-independent, establishing that BRCA1 has genetically separable apoptotic and centrosomal functions in vivo.","evidence":"Conditional KO mouse genetics with p53 and ATM double-KO epistasis, histology, immunofluorescence","pmids":["24639535"],"confidence":"High","gaps":["Centrosomal substrate of BRCA1 E3 ligase in neural progenitors unidentified","Whether neural phenotype contributes to cancer predisposition unknown"]},{"year":2021,"claim":"Cryo-EM structure of BRCA1-BARD1 on a nucleosome revealed how BARD1 recognizes DSB-specific H2A K13/K15 monoubiquitin marks and positions the RING-E2 module to ubiquitinate H2A/H2AX C-terminal tails, explaining chromatin recruitment specificity and substrate selectivity of the heterodimer; concurrently, SIRT2 was shown to deacetylate BARD1 RING lysines to promote BRCA1-BARD1 heterodimerization, stability, and nuclear retention.","evidence":"Cryo-EM structure determination with biochemical ubiquitination and mutagenesis; Co-IP, in vitro deacetylation, HR assay, nuclear fractionation","pmids":["34321665","33789098"],"confidence":"High","gaps":["Full-length BRCA1-BARD1 structure not yet resolved","In vivo dynamics of SIRT2-mediated BARD1 deacetylation during the cell cycle unknown"]},{"year":2024,"claim":"BRCA1 was found to transcriptionally regulate VDAC3 and GPX4, positioning it as a dual regulator of ferroptosis: BRCA1 deficiency blocks VDAC3-dependent ferroptosis while sensitizing cells to GPX4 inhibitor-induced ferroptosis, synergizing with PARP inhibition in BRCA1-deficient cancers.","evidence":"CRISPR/siRNA knockdown, ChIP, ferroptosis assays, xenograft and patient-derived xenograft models","pmids":["38552003"],"confidence":"Medium","gaps":["Whether ferroptosis regulation is a primary tumor-suppressive function or secondary consequence of transcriptional dysregulation","VDAC3/GPX4 regulation not independently replicated"]},{"year":null,"claim":"Key unresolved questions include the full spectrum of physiological BRCA1-BARD1 ubiquitin substrates beyond H2A, the structural basis by which BRCA1 displaces 53BP1/RIF1 at DSBs during S/G2, whether BRCA1's diverse non-repair functions (X-inactivation, ferroptosis regulation, centrosome control) contribute independently to tumor suppression, and how BRCA1 coordinates its scaffolding, enzymatic, and transcriptional activities at a single damage site.","evidence":"","pmids":[],"confidence":"Low","gaps":["Comprehensive substrate identification for BRCA1-BARD1 E3 ligase lacking","Structural mechanism of 53BP1/RIF1 antagonism unresolved","Contribution of individual BRCA1 functions to tissue-specific tumorigenesis unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[5,13,17,18,31]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,13,18,31]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[11,20,21,33]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[10,16,20,21,33]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[31]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[7,14,19]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,3,7,27,30,31,32]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[2,11,13,31]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[2,3,4,6,7,8,23,24,25,31,32]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[3,24,28]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[14,15,19,23,25,35]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[11]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,16,20,21,29,33]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[11,15,31]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,34]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,33,35]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[3,4,8,14,15,25]}],"complexes":["BRCA1-BARD1 heterodimer","BASC (BRCA1-associated genome surveillance complex)","BRCA1-A complex (RAP80/Abraxas/MERIT40/BRCC36/BRE)"],"partners":["BARD1","RAD51","TP53","ABRAXAS1","RAP80","BAP1","FANCD2","RIF1"],"other_free_text":[]},"mechanistic_narrative":"BRCA1 is a nuclear tumor suppressor that functions as a RING-type E3 ubiquitin ligase and central coordinator of the DNA damage response, homologous recombination repair, replication fork protection, and transcriptional regulation. BRCA1 heterodimerizes with BARD1 through its RING domain to ubiquitinate nucleosomal H2A, with substrate specificity determined by BARD1 recognition of DSB-specific monoubiquitin marks on H2A K13/K15 [PMID:34321665]; it is phosphorylated by ATM and ATR kinases at SQ/TQ clusters following DNA damage, which is required for radiation resistance [PMID:10550055, PMID:11114888]. BRCA1 promotes homologous recombination by interacting with RAD51, antagonizing 53BP1/RIF1-mediated end-protection to favor DNA end resection in S/G2 phase, and protecting stalled replication forks from degradation in an epistatic pathway with FANCD2 and RAD51 [PMID:9008167, PMID:10549283, PMID:20453858, PMID:22789542]. Germline loss-of-function mutations in BRCA1 cause hereditary breast and ovarian cancer susceptibility [PMID:7545954]."},"prefetch_data":{"uniprot":{"accession":"P38398","full_name":"Breast cancer type 1 susceptibility protein","aliases":["RING finger protein 53","RING-type E3 ubiquitin transferase BRCA1"],"length_aa":1863,"mass_kda":207.7,"function":"E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage (PubMed:10500182, PubMed:12887909, PubMed:12890688, PubMed:14976165, PubMed:16818604, PubMed:17525340, PubMed:19261748). It is unclear whether it also mediates the formation of other types of polyubiquitin chains (PubMed:12890688). The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability (PubMed:12890688, PubMed:14976165, PubMed:20351172). Regulates centrosomal microtubule nucleation (PubMed:18056443). Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle (PubMed:10724175, PubMed:11836499, PubMed:12183412, PubMed:19261748). Required for FANCD2 targeting to sites of DNA damage (PubMed:12887909). Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation (PubMed:16326698). Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks (PubMed:19369211). Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8 (PubMed:16818604). Acts as a transcriptional activator (PubMed:20160719)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P38398/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BRCA1","classification":"Common Essential","n_dependent_lines":611,"n_total_lines":1208,"dependency_fraction":0.5057947019867549},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"RPS6KA4","stoichiometry":0.2},{"gene":"VCL","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BRCA1","total_profiled":1310},"omim":[{"mim_id":"621363","title":"MAP7 DOMAIN-CONTAINING PROTEIN 1; MAP7D1","url":"https://www.omim.org/entry/621363"},{"mim_id":"621279","title":"LONG INTERGENIC NON-PROTEIN CODING RNA 1011; LINC01011","url":"https://www.omim.org/entry/621279"},{"mim_id":"620693","title":"ASTEROID HOMOLOG 1; ASTE1","url":"https://www.omim.org/entry/620693"},{"mim_id":"620442","title":"BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 5; BROVCA5","url":"https://www.omim.org/entry/620442"},{"mim_id":"619762","title":"KURY-ISIDOR SYNDROME; KURIS","url":"https://www.omim.org/entry/619762"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRCA1"},"hgnc":{"alias_symbol":["RNF53","BRCC1","PPP1R53","FANCS"],"prev_symbol":[]},"alphafold":{"accession":"P38398","domains":[{"cath_id":"3.30.40.10","chopping":"4-98","consensus_level":"high","plddt":85.5901,"start":4,"end":98},{"cath_id":"3.40.50.10190","chopping":"1650-1758","consensus_level":"medium","plddt":94.5132,"start":1650,"end":1758},{"cath_id":"3.40.50.10190","chopping":"1759-1863","consensus_level":"medium","plddt":87.8605,"start":1759,"end":1863}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P38398","model_url":"https://alphafold.ebi.ac.uk/files/AF-P38398-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P38398-F1-predicted_aligned_error_v6.png","plddt_mean":41.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRCA1","jax_strain_url":"https://www.jax.org/strain/search?query=BRCA1"},"sequence":{"accession":"P38398","fasta_url":"https://rest.uniprot.org/uniprotkb/P38398.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P38398/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P38398"}},"corpus_meta":[{"pmid":"11832208","id":"PMC_11832208","title":"Cancer susceptibility and the functions of BRCA1 and BRCA2.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11832208","citation_count":1336,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34081848","id":"PMC_34081848","title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.","date":"2021","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34081848","citation_count":1232,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10549283","id":"PMC_10549283","title":"Brca1 controls homology-directed DNA repair.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10549283","citation_count":1018,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12237281","id":"PMC_12237281","title":"Cancer Incidence in BRCA1 mutation carriers.","date":"2002","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/12237281","citation_count":843,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15343273","id":"PMC_15343273","title":"BRCA1 and BRCA2: 1994 and beyond.","date":"2004","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15343273","citation_count":690,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11114888","id":"PMC_11114888","title":"Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11114888","citation_count":410,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9582019","id":"PMC_9582019","title":"BRCA1 physically associates with p53 and stimulates its transcriptional activity.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9582019","citation_count":409,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18413725","id":"PMC_18413725","title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18413725","citation_count":379,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18851829","id":"PMC_18851829","title":"Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18851829","citation_count":289,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12698198","id":"PMC_12698198","title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12698198","citation_count":281,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10918303","id":"PMC_10918303","title":"Roles of BRCA1 and its interacting proteins.","date":"2000","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10918303","citation_count":257,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10652533","id":"PMC_10652533","title":"Insights into the functions of BRCA1 and BRCA2.","date":"2000","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/10652533","citation_count":252,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12419249","id":"PMC_12419249","title":"BRCA1 supports XIST RNA concentration on the inactive X chromosome.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12419249","citation_count":230,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23486525","id":"PMC_23486525","title":"RIF1 counteracts BRCA1-mediated end resection during DNA repair.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23486525","citation_count":229,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24675954","id":"PMC_24675954","title":"Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.","date":"2014","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24675954","citation_count":215,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7606717","id":"PMC_7606717","title":"Mutation analysis of the BRCA1 gene in ovarian cancers.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7606717","citation_count":205,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8589722","id":"PMC_8589722","title":"BRCA1 is secreted and exhibits properties of a granin.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8589722","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19117993","id":"PMC_19117993","title":"BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19117993","citation_count":179,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19383375","id":"PMC_19383375","title":"The contribution of BRCA1 and BRCA2 to ovarian cancer.","date":"2009","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19383375","citation_count":174,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21203981","id":"PMC_21203981","title":"The role of BRCA1 in DNA damage response.","date":"2010","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/21203981","citation_count":172,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25348513","id":"PMC_25348513","title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25348513","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32877777","id":"PMC_32877777","title":"BAP1: Not just a BRCA1-associated protein.","date":"2020","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32877777","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27241552","id":"PMC_27241552","title":"RANKL/RANK control Brca1 mutation- .","date":"2016","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27241552","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9261099","id":"PMC_9261099","title":"Complex regulation of the BRCA1 gene.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9261099","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11156530","id":"PMC_11156530","title":"Lessons learned from BRCA1 and BRCA2.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11156530","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19261748","id":"PMC_19261748","title":"MERIT40 facilitates BRCA1 localization and DNA damage repair.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19261748","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17643121","id":"PMC_17643121","title":"CCDC98 targets BRCA1 to DNA damage sites.","date":"2007","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17643121","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14711411","id":"PMC_14711411","title":"BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans.","date":"2004","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/14711411","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19887647","id":"PMC_19887647","title":"BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19887647","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22843421","id":"PMC_22843421","title":"Mechanisms of BRCA1 tumor suppression.","date":"2012","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/22843421","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12890739","id":"PMC_12890739","title":"Emerging roles of BRCA1 alternative splicing.","date":"2003","source":"Molecular pathology : MP","url":"https://pubmed.ncbi.nlm.nih.gov/12890739","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34321665","id":"PMC_34321665","title":"Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34321665","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23940229","id":"PMC_23940229","title":"Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.","date":"2013","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23940229","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16633366","id":"PMC_16633366","title":"Is there more to BARD1 than BRCA1?","date":"2006","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16633366","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12214252","id":"PMC_12214252","title":"Roles of BRCA1 in centrosome duplication.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12214252","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15965487","id":"PMC_15965487","title":"BRCA1 participates in DNA decatenation.","date":"2005","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15965487","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22836122","id":"PMC_22836122","title":"Links between genome integrity and BRCA1 tumor suppression.","date":"2012","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22836122","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11016617","id":"PMC_11016617","title":"Estrogens, BRCA1, and breast cancer.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11016617","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15448696","id":"PMC_15448696","title":"Identification of BRCA1-IRIS, a BRCA1 locus product.","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15448696","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26873923","id":"PMC_26873923","title":"Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26873923","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21102443","id":"PMC_21102443","title":"Transcriptional regulation of BRCA1 expression by a metabolic switch.","date":"2010","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21102443","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20820192","id":"PMC_20820192","title":"BRCA1 affects global DNA methylation through regulation of DNMT1.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20820192","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32719340","id":"PMC_32719340","title":"Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32719340","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28884397","id":"PMC_28884397","title":"BRCA1 gene: function and deficiency.","date":"2017","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28884397","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24639535","id":"PMC_24639535","title":"Role of BRCA1 in brain development.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24639535","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23620175","id":"PMC_23620175","title":"In brief: BRCA1 and BRCA2.","date":"2013","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23620175","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26048987","id":"PMC_26048987","title":"Deciphering the BRCA1 Tumor Suppressor Network.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26048987","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24675952","id":"PMC_24675952","title":"\"The race\" to clone BRCA1.","date":"2014","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24675952","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16530420","id":"PMC_16530420","title":"Histopathology of BRCA1- and BRCA2-associated breast cancer.","date":"2006","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16530420","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16172191","id":"PMC_16172191","title":"BRCA1 in hormonal carcinogenesis: basic and clinical research.","date":"2005","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16172191","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14506230","id":"PMC_14506230","title":"BRCA1 associates with processive RNA polymerase II.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14506230","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10528224","id":"PMC_10528224","title":"Emerging roles of BRCA1 in transcriptional regulation and DNA repair.","date":"1999","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10528224","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16108063","id":"PMC_16108063","title":"Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking.","date":"2005","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16108063","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16446310","id":"PMC_16446310","title":"A role for Brca1 in chromosome end maintenance.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16446310","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19770520","id":"PMC_19770520","title":"Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19770520","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20068145","id":"PMC_20068145","title":"Transcriptional autoregulation by BRCA1.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20068145","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15087457","id":"PMC_15087457","title":"DNA damage induces p53-dependent BRCA1 nuclear export.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15087457","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10597248","id":"PMC_10597248","title":"Regulation of BRCA1 by protein degradation.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597248","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7987831","id":"PMC_7987831","title":"The search for BRCA1.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7987831","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15569676","id":"PMC_15569676","title":"The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15569676","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10580847","id":"PMC_10580847","title":"Is TP53 dysfunction required for BRCA1-associated carcinogenesis?","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10580847","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19223511","id":"PMC_19223511","title":"The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19223511","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21673012","id":"PMC_21673012","title":"KIAA0101 interacts with BRCA1 and regulates centrosome number.","date":"2011","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/21673012","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12957814","id":"PMC_12957814","title":"BRCA1 in cancer, cell cycle and genomic stability.","date":"2003","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/12957814","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11733219","id":"PMC_11733219","title":"Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.","date":"2001","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11733219","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23802008","id":"PMC_23802008","title":"BRCA1 in the DNA damage response and at telomeres.","date":"2013","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23802008","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30804228","id":"PMC_30804228","title":"Synergistic lethality between BRCA1 and H3K9me2 loss reflects satellite derepression.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30804228","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10195418","id":"PMC_10195418","title":"The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.","date":"1999","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10195418","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10085126","id":"PMC_10085126","title":"Positive regulation of the BRCA1 promoter.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10085126","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8695765","id":"PMC_8695765","title":"Mutations of the BRCA1 gene in human cancer.","date":"1996","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/8695765","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21799032","id":"PMC_21799032","title":"Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21799032","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16978908","id":"PMC_16978908","title":"Functional assays for BRCA1 and BRCA2.","date":"2006","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16978908","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19843854","id":"PMC_19843854","title":"A role for BRCA1 in uterine leiomyosarcoma.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19843854","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34591954","id":"PMC_34591954","title":"The BRCA1/BARD1 ubiquitin ligase and its substrates.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34591954","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36914836","id":"PMC_36914836","title":"Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis.","date":"2023","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36914836","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38552003","id":"PMC_38552003","title":"BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.","date":"2024","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38552003","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31552267","id":"PMC_31552267","title":"Moving Mountains-The BRCA1 Promotion of DNA Resection.","date":"2019","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31552267","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"13679996","id":"PMC_13679996","title":"BRCA1 and p53: compensatory roles in DNA repair.","date":"2003","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/13679996","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20608970","id":"PMC_20608970","title":"BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20608970","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10403822","id":"PMC_10403822","title":"Casein kinase 2 binds to and phosphorylates BRCA1.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10403822","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16861894","id":"PMC_16861894","title":"BRCA1-mediated ubiquitylation.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16861894","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16357529","id":"PMC_16357529","title":"Assessing the link between BACH1 and BRCA1 in the FA pathway.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16357529","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25260588","id":"PMC_25260588","title":"A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25260588","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20608971","id":"PMC_20608971","title":"BRCA1 16 years later: DNA damage-induced BRCA1 shuttling.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20608971","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9553742","id":"PMC_9553742","title":"BRCA1: a review of structure and putative functions.","date":"1998","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/9553742","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27325824","id":"PMC_27325824","title":"Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage.","date":"2016","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27325824","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11170347","id":"PMC_11170347","title":"Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice.","date":"2001","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/11170347","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19445691","id":"PMC_19445691","title":"Aromatase expression is increased in BRCA1 mutation carriers.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19445691","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33789098","id":"PMC_33789098","title":"SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33789098","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28104682","id":"PMC_28104682","title":"Out-RANKing BRCA1 in Mutation Carriers.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28104682","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12496474","id":"PMC_12496474","title":"Transactivation of repair genes by BRCA1.","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12496474","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17404506","id":"PMC_17404506","title":"BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17404506","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17993233","id":"PMC_17993233","title":"p53, BRCA1 and breast Cancer chemoresistance.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17993233","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23447579","id":"PMC_23447579","title":"TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23447579","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11689934","id":"PMC_11689934","title":"Effect of DNA damage on a BRCA1 complex.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11689934","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15254424","id":"PMC_15254424","title":"Understanding germ-line mutations in BRCA1.","date":"2004","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15254424","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37587346","id":"PMC_37587346","title":"Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37587346","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15254397","id":"PMC_15254397","title":"BRCA1 and transcription.","date":"2004","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15254397","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19484476","id":"PMC_19484476","title":"Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.","date":"2009","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19484476","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35432218","id":"PMC_35432218","title":"BRCA1: An Endocrine and Metabolic Regulator.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35432218","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7545954","id":"PMC_7545954","title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7545954","citation_count":5070,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19553641","id":"PMC_19553641","title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.","date":"2009","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19553641","citation_count":2942,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12677558","id":"PMC_12677558","title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.","date":"2003","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12677558","citation_count":2611,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17525332","id":"PMC_17525332","title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.","date":"2007","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17525332","citation_count":2519,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2270482","id":"PMC_2270482","title":"Linkage of early-onset familial breast cancer to chromosome 17q21.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2270482","citation_count":2022,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23788249","id":"PMC_23788249","title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.","date":"2013","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23788249","citation_count":1945,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10959836","id":"PMC_10959836","title":"A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.","date":"2000","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10959836","citation_count":1685,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14576434","id":"PMC_14576434","title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14576434","citation_count":1672,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20609467","id":"PMC_20609467","title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.","date":"2010","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20609467","citation_count":1415,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17416853","id":"PMC_17416853","title":"Meta-analysis of BRCA1 and BRCA2 penetrance.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17416853","citation_count":1335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9008167","id":"PMC_9008167","title":"Association of BRCA1 with Rad51 in mitotic and meiotic cells.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9008167","citation_count":1278,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19648928","id":"PMC_19648928","title":"Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.","date":"2009","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19648928","citation_count":1144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20609468","id":"PMC_20609468","title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.","date":"2010","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20609468","citation_count":1109,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7939630","id":"PMC_7939630","title":"BRCA1 mutations in primary breast and ovarian carcinomas.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7939630","citation_count":1107,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11239454","id":"PMC_11239454","title":"Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11239454","citation_count":1005,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10500182","id":"PMC_10500182","title":"RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10500182","citation_count":953,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12023992","id":"PMC_12023992","title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.","date":"2002","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12023992","citation_count":953,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18001824","id":"PMC_18001824","title":"RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18001824","citation_count":939,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10783165","id":"PMC_10783165","title":"BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10783165","citation_count":898,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10550055","id":"PMC_10550055","title":"Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.","date":"1999","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10550055","citation_count":847,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15367553","id":"PMC_15367553","title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.","date":"2004","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/15367553","citation_count":837,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18001825","id":"PMC_18001825","title":"RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18001825","citation_count":836,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20453858","id":"PMC_20453858","title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.","date":"2010","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20453858","citation_count":820,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22789542","id":"PMC_22789542","title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.","date":"2012","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22789542","citation_count":796,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9267023","id":"PMC_9267023","title":"Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9267023","citation_count":779,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39764,"output_tokens":6543,"usd":0.108718},"stage2":{"model":"claude-opus-4-6","input_tokens":10225,"output_tokens":4260,"usd":0.236437},"total_usd":0.76372,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":53183,"output_tokens":8438,"usd":0.14306},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12504,"output_tokens":4846,"usd":0.275505}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Brca1-deficient mouse embryonic stem cells have impaired repair of chromosomal DNA double-strand breaks (DSBs) by homologous recombination, and the relative frequencies of homologous vs. nonhomologous DNA integration and DSB repair are altered, demonstrating a caretaker role for BRCA1 in promoting homologous recombination and limiting mutagenic nonhomologous repair.\",\n      \"method\": \"Loss-of-function in mouse ES cells (Brca1-deficient), chromosomal DSB repair frequency assays measuring homologous vs. nonhomologous integration\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO ES cells with defined molecular phenotype, replicated across labs and foundational paper with >1000 citations\",\n      \"pmids\": [\"10549283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ATR kinase directly phosphorylates BRCA1 on six Ser/Thr residues including Ser1423 in vitro and in vivo in response to UV, hydroxyurea, and aphidicolin; ATR and BRCA1 co-localize in nuclear foci at stalled replication forks, placing ATR and BRCA1 in the same genotoxic stress-responsive pathway.\",\n      \"method\": \"In vitro kinase assay, dominant-negative ATR expression, site-directed mutagenesis of phosphorylation sites, immunofluorescence co-localization, doxycycline-inducible kinase-dead ATR mutant\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro phosphorylation assay with mutagenesis plus in vivo validation with dominant-negative system; highly cited\",\n      \"pmids\": [\"11114888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BRCA1 physically interacts with p53 both in vitro and in vivo, mapping to aa 224–500 of BRCA1 and the C-terminal domain of p53; BRCA1 co-activates p53-dependent transcription from p21WAF1/CIP1 and bax promoters, and tumor-derived BRCA1 mutants are defective in this co-activation.\",\n      \"method\": \"Co-immunoprecipitation in vivo, in vitro binding assay, transactivation reporter assay, dominant-negative truncation mutant analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus in vitro binding plus functional reporter assay with mutagenesis; highly cited\",\n      \"pmids\": [\"9582019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BAP1 (a ubiquitin C-terminal hydrolase) interacts with BARD1 through residues 182–365 and interferes with BRCA1/BARD1 E3 ligase activity by competing with BRCA1 for BARD1 binding and inhibiting BRCA1 autoubiquitination and NPM1/B23 ubiquitination; a catalytically inactive BAP1 C91S mutant still inhibits ubiquitination, indicating a second non-catalytic mechanism.\",\n      \"method\": \"Co-immunoprecipitation, surface plasmon resonance (BIAcore), in vitro ubiquitination assay, catalytic mutant (C91S), shRNA knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro biochemical reconstitution with SPR, mutagenesis, and in vivo validation\",\n      \"pmids\": [\"19117993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of BRCA1-BARD1 on a nucleosome reveals that the ankyrin repeat and tandem BRCT domains of BARD1 bind nucleosomal histones, DNA, and monoubiquitin on H2A K13/K15; RING domains in BRCA1-BARD1 orient an E2 ubiquitin-conjugating enzyme atop the nucleosome for ubiquitin transfer to the C-terminal tails of H2A/H2AX; recognition of monoubiquitin at H2A N-terminus blocks polyubiquitin chain formation and cooperatively promotes C-terminal H2A ubiquitylation.\",\n      \"method\": \"Cryo-electron microscopy structural determination, functional validation of ubiquitylation specificity\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with functional validation; highly cited\",\n      \"pmids\": [\"34321665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCDC98 (Abraxas) is a component of the BRCA1-RAP80 complex that mediates BRCA1's association with RAP80 and controls DNA damage-induced BRCA1 foci formation and BRCA1-dependent G2/M checkpoint activation.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence foci assay, G2/M checkpoint assay, RNAi knockdown\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identification of complex component plus functional checkpoint and localization assays\",\n      \"pmids\": [\"17643121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MERIT40 is a component of the RAP80/CCDC98 (Abraxas)-containing BRCA1-A complex that directly interacts with BRE/BRCC45; MERIT40 regulates BRCA1 retention at DNA breaks and checkpoint function by maintaining stability of the five-subunit complex at DNA damage sites.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence foci assay, checkpoint assay, RNAi knockdown\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP complex identification with functional localization and checkpoint readouts\",\n      \"pmids\": [\"19261748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RIF1 translocates to DNA damage sites via ATM-dependent 53BP1 phosphorylation and counteracts BRCA1-mediated DNA end resection; loss of RIF1 rescues initial DNA end resection and checkpoint activation in BRCA1-depleted cells; BRCA1 antagonizes RIF1 accumulation at damage sites in S and G2 phases, while RIF1 inhibits BRCA1 translocation in G1 phase.\",\n      \"method\": \"RNAi knockdown, immunofluorescence foci assay, resection assay, checkpoint activation assay, epistasis analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with clean KD and multiple orthogonal functional readouts\",\n      \"pmids\": [\"23486525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRCA1 interacts and colocalizes with topoisomerase IIα in S-phase cells; BRCA1-deficient cells show lagging chromosomes and defective DNA decatenation in vitro; topoisomerase IIα is ubiquitinated in a BRCA1-dependent manner, and this ubiquitination correlates with higher DNA decatenation activity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro decatenation assay, immunofluorescence, in vitro ubiquitination assay\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro decatenation assay plus in vitro ubiquitination plus Co-IP, with BRCA1-deficient cells\",\n      \"pmids\": [\"15965487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRCA1 colocalizes with markers of the inactive X chromosome (Xi) in female somatic cells, associates with XIST RNA (detected by chromatin immunoprecipitation), and is required to maintain XIST RNA concentration on Xi; loss of BRCA1 leads to defects in Xi chromatin structure and increased expression of a silenced Xi-located GFP transgene.\",\n      \"method\": \"Immunofluorescence co-localization, chromatin immunoprecipitation, BRCA1 reconstitution in deficient cells, GFP reporter assay for Xi silencing\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus functional reporter assay plus reconstitution experiment; highly cited\",\n      \"pmids\": [\"12419249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BRCA1-IRIS, a BRCA1 locus product encoded by a reading frame extending into intron 11, is exclusively chromatin-associated, does not interact with BARD1, co-immunoprecipitates with DNA replication licensing proteins and replication initiation sites; suppression of BRCA1-IRIS hindered departure of geminin from pre-replication complexes and depressed DNA replication rate, while overexpression stimulated DNA replication.\",\n      \"method\": \"Co-immunoprecipitation, chromatin fractionation, RNAi knockdown, overexpression with DNA replication rate measurement\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional overexpression/knockdown, single lab\",\n      \"pmids\": [\"15448696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRCA1 binds the SIRT1 promoter and increases SIRT1 expression; SIRT1 in turn inhibits Survivin by altering epigenetic modification of histone H3; absence of SIRT1 blocks BRCA1's regulation of Survivin.\",\n      \"method\": \"Chromatin immunoprecipitation, gene expression analysis, genetic rescue experiments in Brca1 mutant mice, in vitro and in vivo mouse models\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus genetic epistasis in mouse model, single lab\",\n      \"pmids\": [\"18851829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRCA1 represses estrogen receptor-α (ER-α) activity by regulating its post-translational modification: BRCA1 overexpression reduces acetylated ER-α and promotes mono-ubiquitination of ER-α at K302; a BRCA1 RING mutant defective for ubiquitin ligase activity (I26A) does not ubiquitinate ER-α or repress its activity; wild-type BRCA1 but not cancer mutant C61G inhibits p300-mediated acetylation of ER-α in vitro.\",\n      \"method\": \"In vitro ubiquitination assay, in vitro acetylation assay, RNAi knockdown, overexpression with mutant analysis (I26A, C61G), co-immunoprecipitation\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro biochemical assays plus mutagenesis, single lab\",\n      \"pmids\": [\"19887647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The BRCA1/BARD1 heterodimer functions as a RING-type E3 ubiquitin ligase, and this activity is conserved in C. elegans BRC-1/BRD-1; depletion of Ce-brc-1 or Ce-brd-1 causes elevated p53-dependent germ cell death, impaired progeny survival, and chromosome fragmentation after irradiation, establishing a shared role in DNA repair.\",\n      \"method\": \"RNAi depletion in C. elegans, genetic analysis (epistasis), irradiation sensitivity, chromosome fragmentation assay, protein interaction screen\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — C. elegans ortholog functional genetic analysis with multiple phenotypic readouts\",\n      \"pmids\": [\"14711411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 binds the DNMT1 promoter through a potential OCT1 site and is required for maintaining transcriptionally active DNMT1 promoter configuration; impaired BRCA1 function leads to global DNA hypomethylation, loss of genomic imprinting, and open chromatin in mouse tissues.\",\n      \"method\": \"Chromatin immunoprecipitation, BRCA1 mutant mouse model, methylation analysis, gene expression assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus in vivo mouse model, single lab\",\n      \"pmids\": [\"20820192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The BRCA1 RING and BRCT domains must cooperate for efficient targeting of BRCA1 to ionizing radiation-induced nuclear foci; BRCT domain cancer mutations abolish recruitment to foci while RING domain alone is insufficient; only combined RING-BRCT fusion restores foci targeting, co-localizing with MDC1.\",\n      \"method\": \"Fluorescence imaging of YFP-tagged BRCA1 domain constructs in MCF-7 cells, ionizing radiation-induced foci assay, cancer mutation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with domain dissection and cancer mutant validation, single lab\",\n      \"pmids\": [\"15569676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DNA damage induces BRCA1 nuclear export in a CRM1-dependent and p53-dependent manner; ionizing radiation stimulates BRCA1 nuclear export in a dose-dependent fashion across all cell cycle phases, regulated by p53 and CRM1 pathway.\",\n      \"method\": \"Immunohistochemical staining, subcellular fractionation, Western blotting, CRM1 inhibitor (leptomycin B), p53 manipulation (E6 protein, tetracycline-inducible system)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — fractionation plus multiple cell systems with functional validation, single lab\",\n      \"pmids\": [\"15087457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Casein kinase 2 (CK2) β-subunit associates with the C-terminal region of BRCA1 (identified by yeast two-hybrid and confirmed in Sf9 cells), and CK2 phosphorylates BRCA1 in vitro at serine 1572; a tumor-associated missense mutation (M1775R) weakens the CK2β-BRCA1 interaction.\",\n      \"method\": \"Yeast two-hybrid, co-expression in Sf9 cells, in vitro kinase assay, site-directed mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay with mutagenesis, but single lab and limited follow-up\",\n      \"pmids\": [\"10403822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BRCA1 interacts specifically with hyperphosphorylated (processive) RNA polymerase II (IIO form) rather than the hypophosphorylated promoter-associated form (IIA); BRCA1-RNA pol II complexes are transcriptionally active in run-off assays; DNA-damaging agents disrupt this interaction.\",\n      \"method\": \"Biochemical fractionation, co-immunoprecipitation, transcriptional run-off assay, DNA damage treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with biochemical fractionation and functional transcription assay, single lab\",\n      \"pmids\": [\"14506230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SIRT2 deacetylase complexes with BRCA1-BARD1 and deacetylates conserved lysines in the BARD1 RING domain at the BRCA1-BARD1 interface, promoting BRCA1-BARD1 heterodimerization, mutual stability, nuclear retention, localization to DNA damage sites, and efficient homologous recombination.\",\n      \"method\": \"Co-immunoprecipitation, deacetylation assay, RNAi knockdown, immunofluorescence foci assay, HR assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus biochemical deacetylation assay plus functional HR readout, single lab\",\n      \"pmids\": [\"33789098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Brca1-deficient T-cells display telomere dysfunction including loss of telomere repeats and defective telomere capping; loss of Brca1 synergizes with p53 deficiency in tumorigenesis; thymic lymphomas from Brca1/p53 double-KO show telomere dysfunction and clonal chromosomal translocations.\",\n      \"method\": \"Mouse knockout model, telomere FISH, karyotyping, tumor incidence analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mouse KO with direct telomere measurement and chromosomal analysis, single lab\",\n      \"pmids\": [\"16446310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 transcription is controlled by a dynamic equilibrium between coactivators and co-repressors governing histone acetylation at the BRCA1 promoter; CtBP acts as a transcriptional co-repressor at the BRCA1 promoter through HDAC1; loss of CtBP by estrogen induction, RNAi, or increased NAD+/NADH ratio leads to HDAC1 dismissal, elevated histone acetylation, and increased BRCA1 transcription.\",\n      \"method\": \"Chromatin immunoprecipitation, RNAi knockdown, estrogen stimulation, HDAC1 ChIP, reporter assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with multiple perturbations, single lab\",\n      \"pmids\": [\"21102443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 assembles with E2F-1 and RB to form a repressive multicomponent transcriptional complex that inhibits BRCA1 promoter transcription in an autoregulatory loop; genotoxic stress displaces BRCA1 from the BRCA1 promoter and upregulates BRCA1 transcription; demonstrated by tandem ChIP.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP and tandem ChIP), RNAi knockdown, overexpression, reporter assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — tandem ChIP plus functional reporter assay plus KD/OE, single lab\",\n      \"pmids\": [\"20068145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRCA1 localizes to centrosomes and binds γ-tubulin; targeted disruption of murine Brca1 results in centrosome amplification, indicating BRCA1 serves as a negative regulator of centrosome duplication.\",\n      \"method\": \"Immunofluorescence localization, co-immunoprecipitation with γ-tubulin, mouse knockout centrosome analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — localization plus Co-IP plus KO phenotype, review summarizing experimental data\",\n      \"pmids\": [\"12214252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCA1 promotes transcription of VDAC3 and GPX4; BRCA1 deficiency promotes resistance to erastin-induced (VDAC3-dependent) ferroptosis but sensitizes cells to GPX4 inhibitor-induced ferroptosis; NCOA4-mediated ferritinophagy and defective GPX4 induction together unleash ferroptosis in BRCA1-deficient cells upon co-treatment with PARP and GPX4 inhibitors.\",\n      \"method\": \"Chromatin immunoprecipitation, gene expression analysis, BRCA1 KO/KD, ferroptosis assays, xenograft tumor models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus in vitro and in vivo functional assays, single lab\",\n      \"pmids\": [\"38552003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The BRCA1-CtIP complex is stable in irradiated cells; phosphorylated isoforms of CtIP induced by ionizing radiation (via ATM at S664 and S745) still interact in vivo with BRCA1, as the BRCA1-binding domain of CtIP (residues 133–369) is distal to ATM phosphorylation sites.\",\n      \"method\": \"Co-immunoprecipitation in irradiated cells, domain mapping, phosphorylation site analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with domain mapping, single lab\",\n      \"pmids\": [\"11689934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BRCA1 steady-state protein level is regulated by proteolytic degradation via a cathepsin-like (lysosomal) protease, not the proteasome; protease inhibitor ALLN stabilizes BRCA1 by prolonging its half-life without affecting mRNA levels; selective calpain inhibitors and lysosomal inhibitors (chloroquine, bafilomycin) also stabilize BRCA1.\",\n      \"method\": \"Pharmacological inhibitor panel (proteasome, calpain, cathepsin inhibitors), pulse-chase/protein half-life analysis, Western blotting of subcellular fractions\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibitor approach without genetic validation of specific protease, single lab\",\n      \"pmids\": [\"10597248\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRCA1 functions as a multidomain tumor suppressor that forms distinct nuclear complexes (including BRCA1-A with RAP80/CCDC98/MERIT40/BRE/BRCC36, and complexes with BARD1, CtIP, and PALB2/BRCA2) to promote homologous recombination repair of DNA double-strand breaks, acts as a RING-type E3 ubiquitin ligase with BARD1 to ubiquitylate nucleosomal H2A at K13/K15 (promoting HR over NHEJ by opposing 53BP1/RIF1), is phosphorylated by ATM and ATR at multiple sites in response to DNA damage, regulates centrosome duplication, DNA decatenation (via topoisomerase IIα ubiquitination), telomere integrity, X-chromosome inactivation (through XIST RNA stabilization), and transcription (including autoregulation, ER-α repression via mono-ubiquitination, and DNMT1/SIRT1/GPX4 promoter activation), with its subcellular localization regulated by SIRT2-mediated BARD1 deacetylation, CRM1-dependent nuclear export, and p53-dependent damage-induced cytoplasmic shuttling.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"BRCA1 was positionally cloned on chromosome 17q21, encoding a predicted 1863-amino-acid protein with a zinc finger domain in its amino-terminal region; probable predisposing mutations (frameshift, nonsense, missense, regulatory) were identified in familial breast/ovarian cancer kindreds.\",\n      \"method\": \"Positional cloning, mutation sequencing, linkage analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original positional cloning with mutation identification, foundational discovery paper with >5000 citations\",\n      \"pmids\": [\"7545954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"A susceptibility locus for early-onset familial breast cancer was mapped to chromosome 17q21 by linkage analysis, establishing the chromosomal location of BRCA1.\",\n      \"method\": \"Genetic linkage analysis (LOD score analysis of RFLP markers)\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mapping with high LOD score, foundational discovery replicated across families\",\n      \"pmids\": [\"2270482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BRCA1 colocalizes with RAD51 in discrete nuclear foci during S phase of the cell cycle, co-immunoprecipitates with RAD51, and BRCA1 residues 758–1064 alone form RAD51-containing complexes in vitro; both proteins associate with synaptonemal complexes in meiotic cells, suggesting a functional interaction in recombination and genome integrity control.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, immunofluorescence colocalization, meiotic chromosome spreads\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus in vitro domain mapping, replicated in mitotic and meiotic contexts\",\n      \"pmids\": [\"9008167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BRCA1 localizes to discrete S-phase nuclear foci that disperse upon DNA damage (UV, gamma-irradiation, mitomycin C, hydroxyurea); dispersal is accompanied by DNA damage-induced hyperphosphorylation of BRCA1 and redistribution of BRCA1/BARD1/RAD51 complexes to PCNA-positive replication structures, implicating BRCA1-containing complexes in a replication checkpoint response.\",\n      \"method\": \"Immunofluorescence, cell fractionation, Western blot phosphorylation shift analysis, co-immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, dynamic phosphorylation and relocalization directly linked to DNA damage response\",\n      \"pmids\": [\"9267023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ATM kinase is required for BRCA1 phosphorylation in response to ionizing radiation; ATM resides in a complex with BRCA1 and phosphorylates BRCA1 in vivo and in vitro at serine-glutamine clusters; a BRCA1 mutant lacking two ATM phosphorylation sites fails to rescue radiation hypersensitivity of BRCA1-deficient cells.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, complementation of radiation hypersensitivity\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus mutagenesis rescue experiment, functionally validated\",\n      \"pmids\": [\"10550055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BRCA1 RING finger domain mediates E2-dependent ubiquitination; mutations of metal-coordinating residues in the RING finger abolish ubiquitination activity, establishing BRCA1 as a RING-type E3 ubiquitin ligase.\",\n      \"method\": \"In vitro ubiquitination assay, mutagenesis of RING finger zinc-coordinating residues, chelation of zinc\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro ubiquitination with mutagenesis controls\",\n      \"pmids\": [\"10500182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Brca1-deficient mouse embryonic stem cells have impaired repair of chromosomal double-strand breaks by homologous recombination, with altered frequencies of homologous versus nonhomologous DNA integration, demonstrating a caretaker role for BRCA1 in promoting homologous recombination.\",\n      \"method\": \"Gene targeting, DSB repair frequency assay in ES cells, Southern blotting\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined molecular phenotype in homologous recombination assay\",\n      \"pmids\": [\"10549283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BRCA1 associates with a large nuclear surveillance complex (BASC) containing MSH2, MSH6, MLH1, ATM, BLM, RAD50-MRE11-NBS1, and RFC; BRCA1, BLM, and RAD50-MRE11-NBS1 colocalize to nuclear foci containing PCNA after agents that block DNA synthesis, placing BRCA1 as a coordinator of multiple DNA repair and replication activities.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry, co-immunoprecipitation, immunofluorescence colocalization\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mass spectrometry-based complex identification plus co-IP and colocalization, widely replicated\",\n      \"pmids\": [\"10783165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ATR kinase phosphorylates BRCA1 on six Ser/Thr residues including Ser1423 in vitro; kinase-inactive ATR suppresses Ser1423 phosphorylation after HU or UV treatment; ATR forms nuclear foci overlapping BRCA1 foci at stalled replication forks, demonstrating ATR directly phosphorylates BRCA1 in response to DNA damage or replication stress.\",\n      \"method\": \"In vitro kinase assay, dominant-negative ATR expression, immunofluorescence colocalization, phospho-specific antibodies\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus dominant-negative rescue experiment with phospho-site mapping\",\n      \"pmids\": [\"11114888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FANCD2, activated by monoubiquitination through a nuclear FA complex (FANCA/FANCC/FANCF/FANCG), colocalizes with BRCA1 in ionizing radiation-induced nuclear foci and on synaptonemal complexes, linking the Fanconi anemia pathway to the BRCA1 DNA repair machinery.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence colocalization, Western blot (monoubiquitination shift), cell fractionation\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and colocalization in multiple contexts, widely replicated\",\n      \"pmids\": [\"11239454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BRCA1 physically associates with p53 in vitro and in vivo, mapping to BRCA1 aa 224–500 and the p53 C-terminal domain; BRCA1 stimulates p53-dependent transcription from p21WAF1/CIP1 and bax promoters; tumor-derived BRCA1 mutants are defective in p53 co-activation; BRCA1 and p53 cooperatively induce apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transient transfection transcriptional reporter assay, apoptosis assay, domain mapping\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo binding with domain mapping plus functional transcriptional assays\",\n      \"pmids\": [\"9582019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRCA1 colocalizes with markers of the inactive X chromosome and associates with XIST RNA (detected by ChIP); reconstitution of BRCA1-deficient cells with wild-type BRCA1 restores focal XIST RNA staining; inhibiting BRCA1 synthesis in a reporter line leads to increased expression of a silenced Xi-located GFP transgene, demonstrating BRCA1 supports XIST RNA concentration and inactive X chromosome maintenance.\",\n      \"method\": \"Immunofluorescence colocalization, chromatin immunoprecipitation, reconstitution assay, GFP reporter gene expression assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus functional reconstitution and reporter gene assay\",\n      \"pmids\": [\"12419249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"C. elegans BRC-1 (BRCA1 ortholog) and BRD-1 (BARD1 ortholog) are required for DNA repair; their depletion causes elevated p53-dependent germ cell death, impaired progeny survival after irradiation, and chromosome fragmentation, functionally conserving the BRCA1/BARD1 repair pathway.\",\n      \"method\": \"RNAi depletion, irradiation survival assay, genetic epistasis, cytological analysis\",\n      \"journal\": \"Current Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in model organism with defined DNA repair phenotype, consistent with mammalian function\",\n      \"pmids\": [\"14711411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRCA1 interacts and colocalizes with topoisomerase IIα in S-phase cells; BRCA1-deficient cells show lagging chromosomes and defective DNA decatenation in vitro; topoisomerase IIα is ubiquitinated in a BRCA1-dependent manner, and this ubiquitination correlates with higher decatenation activity, revealing a BRCA1 role in DNA decatenation and chromosome segregation.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, in vitro decatenation assay, chromosome analysis, ubiquitination assay\",\n      \"journal\": \"Nature Structural & Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro activity assay plus Co-IP, ubiquitination, and functional genetic analysis\",\n      \"pmids\": [\"15965487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCDC98 (Abraxas) mediates BRCA1 association with RAP80 and is required for DNA damage-induced BRCA1 nuclear foci formation and BRCA1-dependent G2/M checkpoint activation.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, siRNA knockdown, checkpoint assay\",\n      \"journal\": \"Nature Structural & Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional checkpoint assay with KD\",\n      \"pmids\": [\"17643121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RNF8 ubiquitylates histone H2A and H2AX at DNA double-strand breaks via its RING domain after phospho-dependent binding to MDC1 through its FHA domain; this ubiquitylation is required for accumulation of BRCA1 (and 53BP1) at DSB sites; RNF8 depletion impairs G2/M checkpoint and increases IR sensitivity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination, siRNA knockdown, immunofluorescence, checkpoint assay, X-ray crystallography of FHA domain\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus in vitro ubiquitination and functional genetic analysis\",\n      \"pmids\": [\"18001824\", \"18001825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRCA1 binds the SIRT1 promoter and increases SIRT1 expression; SIRT1 in turn inhibits Survivin by altering histone H3 epigenetic modifications; absence of SIRT1 blocks BRCA1-mediated Survivin regulation; demonstrated in Brca1-mutant mouse mammary tumors and in vitro.\",\n      \"method\": \"Chromatin immunoprecipitation, promoter reporter assay, siRNA knockdown, Western blot, mouse tumor model\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and functional siRNA rescue, single lab\",\n      \"pmids\": [\"18851829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BAP1 (ubiquitin C-terminal hydrolase) interacts with the BARD1 RING domain (residues 182–365 of BAP1) via surface plasmon resonance; BAP1 interferes with BRCA1/BARD1 heterodimerization, inhibiting BRCA1/BARD1 autoubiquitination and NPM1/B23 ubiquitination; a catalytically inactive BAP1 mutant (C91S) also inhibits ubiquitination, indicating a second steric mechanism; BAP1 depletion causes IR hypersensitivity and S-phase retardation.\",\n      \"method\": \"Surface plasmon resonance (BIAcore), in vitro ubiquitination assay, catalytic mutant analysis, shRNA knockdown, cell cycle assay\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biophysical binding assay plus in vitro ubiquitination with mutagenesis and functional cellular phenotype\",\n      \"pmids\": [\"19117993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRCA1 overexpression reduces acetylated ER-α levels and increases mono-ubiquitinated ER-α; a BRCA1 ubiquitin ligase-dead mutant (I26A) neither ubiquitinates ER-α nor represses its activity; in vitro, BRCA1 inhibits p300-mediated acetylation of ER-α; a cancer-associated BRCA1 mutant (C61G) lacks this activity, linking BRCA1 E3 ligase activity to regulation of ER-α via competing acetylation/ubiquitination.\",\n      \"method\": \"In vitro ubiquitination assay, in vitro acetylation assay, siRNA knockdown, Western blot, transient transfection reporter assay\",\n      \"journal\": \"Molecular Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assays plus mutagenesis and cellular functional assay\",\n      \"pmids\": [\"19887647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MERIT40 is a component of the RAP80/CCDC98-containing BRCA1-A complex; it interacts directly with BRE/BRCC45 to maintain complex stability; MERIT40 is required for BRCA1 retention at DNA breaks and for checkpoint function.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, immunofluorescence foci assay, checkpoint assay, protein stability assay\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with functional siRNA knockdown and defined checkpoint phenotype\",\n      \"pmids\": [\"19261748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 deficiency leads to global DNA hypomethylation and loss of genomic imprinting; BRCA1 binds the DNMT1 promoter through a potential OCT1 site and maintains transcriptional activity of DNMT1; demonstrated in BRCA1-mutant mouse models and human clinical samples.\",\n      \"method\": \"Chromatin immunoprecipitation, promoter assay, bisulfite sequencing, mouse knockout model, Western blot\",\n      \"journal\": \"Cell Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and promoter analysis with in vivo mouse model, single lab\",\n      \"pmids\": [\"20820192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 assembles with E2F-1 and RB to form a repressive transcriptional complex at the BRCA1 promoter; genotoxic stress disrupts this complex, displacing BRCA1 and upregulating BRCA1 transcription, defining an autoregulatory loop; demonstrated by tandem ChIP.\",\n      \"method\": \"Tandem chromatin immunoprecipitation (Re-ChIP), siRNA knockdown, promoter reporter assay, Western blot\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — tandem ChIP with functional siRNA analysis, single lab\",\n      \"pmids\": [\"20068145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 expression is controlled by a CtBP-containing co-repressor complex regulating HDAC1 and histone acetylation at the BRCA1 promoter; eviction of CtBP by estrogen, siRNA, or elevated NAD+/NADH leads to HDAC1 dismissal and increased BRCA1 transcription, revealing a metabolic switch coupling caloric intake to tumor suppressor expression.\",\n      \"method\": \"Chromatin immunoprecipitation, siRNA knockdown, NAD+/NADH metabolic manipulation, HDAC inhibitor treatment, promoter reporter assay\",\n      \"journal\": \"Nature Structural & Molecular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with mechanistic metabolic manipulation, single lab\",\n      \"pmids\": [\"21102443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of 53BP1 rescues the growth arrest, checkpoint defects, and partially rescues the homologous recombination defect and DNA damage hypersensitivity of Brca1-deleted cells; 53BP1 acts downstream of ATM to sustain the checkpoint response in BRCA1-deficient cells; this rescue is specific to BRCA1 (not BRCA2) deficiency, defining an epistatic relationship between BRCA1 and the 53BP1 pathway in DNA repair pathway choice.\",\n      \"method\": \"Conditional knockout mouse cells, siRNA knockdown, HR assay, checkpoint assay, drug hypersensitivity assay\",\n      \"journal\": \"Nature Structural & Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in clean KO cells with multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"20453858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FANCD2 and BRCA1 are required for protection of stalled replication forks from degradation in a repair-independent manner; this fork protection is epistatic with RAD51 stabilization, linking FA genes, RAD51, and BRCA1/2 in a unified fork protection pathway.\",\n      \"method\": \"DNA fiber assay (replication fork degradation), siRNA knockdown, RAD51 overexpression rescue, genetic epistasis\",\n      \"journal\": \"Cancer Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — DNA fiber assay with epistasis and rescue experiments\",\n      \"pmids\": [\"22789542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RIF1 translocates to DNA damage sites via ATM-dependent 53BP1 phosphorylation and counteracts BRCA1-mediated DNA end resection; loss of RIF1 rescues end resection and checkpoint activation in BRCA1-depleted cells; BRCA1 antagonizes RIF1 accumulation at damage sites in S/G2, while RIF1 inhibits BRCA1 recruitment in G1; RIF1 also promotes BLM chromatin loading independently of 53BP1.\",\n      \"method\": \"siRNA knockdown, immunofluorescence foci assay, end resection assay, checkpoint assay, cell cycle fractionation\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis analysis with multiple KDs and cell-cycle-specific mechanistic dissection\",\n      \"pmids\": [\"23486525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Casein kinase 2 beta-subunit binds BRCA1 C-terminal region (identified by yeast two-hybrid and confirmed in Sf9 cells); CK2 phosphorylates BRCA1 in vitro, requiring Ser1572; the cancer-associated missense mutant M1775R shows weaker CK2 association.\",\n      \"method\": \"Yeast two-hybrid, in vitro kinase assay, site-directed mutagenesis, Sf9 cell expression\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–3 — in vitro kinase assay with mutagenesis but limited cellular validation\",\n      \"pmids\": [\"10403822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The BRCA1 RING and BRCT domains cooperate to target BRCA1 to ionizing radiation-induced nuclear foci; cancer-specific mutations in the BRCT domain abolish foci recruitment; neither domain alone is sufficient, but their combination restores foci targeting, co-localizing with MDC1.\",\n      \"method\": \"YFP-BRCA1 domain mapping in MCF-7 cells, immunofluorescence after ionizing radiation, dominant-negative competition\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — domain-deletion live-cell imaging with functional competition assay, single lab\",\n      \"pmids\": [\"15569676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BRCA1-IRIS, a distinct BRCA1 locus product encoded from codon 1 through intron 11, is exclusively chromatin-associated, does not interact with BARD1 in vivo or in vitro, co-immunoprecipitates with DNA replication-licensing proteins, and suppression of BRCA1-IRIS impairs DNA replication initiation while overexpression stimulates it. [Note: classified as a distinct protein isoform/alt product from the BRCA1 locus; KEEP as it describes a direct protein product and its mechanistic distinction from p220 BRCA1 is itself a mechanistic finding about the locus.]\",\n      \"method\": \"Co-immunoprecipitation, immunostaining, BRCA1-IRIS siRNA knockdown, DNA replication assay, chromatin fractionation\",\n      \"journal\": \"Nature Cell Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with functional replication assay and siRNA knockdown, single lab\",\n      \"pmids\": [\"15448696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BRCA1 associates specifically with hyperphosphorylated, elongating RNA polymerase II (pol IIO) rather than the hypophosphorylated initiating form (pol IIA); BRCA1-RNA pol II complexes are functional in transcriptional run-off assays; interaction is disrupted by DNA-damaging agents, placing BRCA1 in position to link processive transcription with DNA repair surveillance.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation, in vitro transcriptional run-off assay, phospho-specific antibodies\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with in vitro functional assay, single lab\",\n      \"pmids\": [\"14506230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Ionizing radiation stimulates BRCA1 nuclear export in a dose-dependent and CRM1-dependent manner; this export requires wild-type p53 function (abrogated by HPV E6); BRCA1 localization varies across the cell cycle and is regulated by p53-dependent mechanisms in addition to kinase-dependent phosphorylation.\",\n      \"method\": \"Immunohistochemical staining, subcellular fractionation and Western blot, CRM1 inhibitor (leptomycin B), inducible p53 system, cell cycle fractionation\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods with genetic p53 requirement established, single lab\",\n      \"pmids\": [\"15087457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of BRCA1-BARD1 on a nucleosome reveals that BARD1 ankyrin repeat and tandem BRCT domains adopt a compact fold binding nucleosomal histones, DNA, and monoubiquitin on H2A K13/K15 (DSB-specific marks); RING domains orient an E2 enzyme atop the nucleosome for ubiquitin transfer to H2A/H2AX C-terminal tails; recognition of N-terminal H2A monoubiquitin blocks polyubiquitin chain formation and cooperatively promotes C-terminal H2A ubiquitylation, explaining BRCA1-BARD1 chromatin recruitment and specificity.\",\n      \"method\": \"Cryo-electron microscopy structure determination, biochemical ubiquitination assay, mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with biochemical validation and mutagenesis, single high-quality paper with orthogonal methods\",\n      \"pmids\": [\"34321665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SIRT2 deacetylase complexes with BRCA1-BARD1 and deacetylates conserved lysines in the BARD1 RING domain at the BRCA1-BARD1 interface, promoting heterodimerization, mutual stability, nuclear retention, and localization to DNA damage sites, thereby facilitating homologous recombination.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deacetylation assay, siRNA knockdown, nuclear fractionation, HR assay, immunofluorescence\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic assay with Co-IP, subcellular fractionation, and functional HR assay\",\n      \"pmids\": [\"33789098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCA1 promotes transcription of VDAC3 and GPX4; BRCA1 deficiency blocks VDAC3-dependent erastin-induced ferroptosis but sensitizes cells to GPX4 inhibitor-induced ferroptosis; NCOA4-mediated ferritinophagy and defective GPX4 induction synergize with PARP inhibition to induce ferroptosis in BRCA1-deficient cancers, revealing a dual regulatory role for BRCA1 in ferroptosis.\",\n      \"method\": \"siRNA/CRISPR knockdown, transcriptional reporter/ChIP, ferroptosis assays (cell viability, lipid peroxidation), xenograft tumor models, patient-derived xenograft\",\n      \"journal\": \"Cancer Discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with functional loss-of-function assays and in vivo xenograft, single lab\",\n      \"pmids\": [\"38552003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Loss of Brca1 in mouse T-cells results in telomere dysfunction including loss of telomere repeats and defective telomere capping; Brca1 synergizes with p53 deficiency to promote tumorigenesis with clonal chromosomal translocations arising from telomere dysfunction.\",\n      \"method\": \"Conditional knockout mouse model, telomere FISH, karyotyping, tumor incidence analysis\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with direct cytological telomere analysis and functional tumor phenotype\",\n      \"pmids\": [\"16446310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Neural progenitor-specific deletion of BRCA1 in developing mouse brain causes severe agenesis of neocortex, hippocampus, cerebellum, and olfactory bulbs primarily through excess p53-dependent apoptosis; centrosomal/cell polarity phenotypes are not rescued by p53 co-deletion but are partially rescued by ATM co-deletion, demonstrating distinct apoptotic and centrosomal functions of BRCA1 in neural progenitors.\",\n      \"method\": \"Conditional knockout mouse genetics, histology, p53 and ATM double-KO epistasis, immunofluorescence\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with double-KO epistasis to dissect distinct functions\",\n      \"pmids\": [\"24639535\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRCA1 is a multifunctional nuclear tumor suppressor that acts as a RING-type E3 ubiquitin ligase (heterodimerizing with BARD1, with specificity for nucleosomal H2A determined by cryo-EM structure), promotes homologous recombination repair of DNA double-strand breaks (via RAD51 interaction and DNA end resection antagonizing 53BP1/RIF1), is phosphorylated by ATM (at SQ clusters) and ATR (at Ser1423) after DNA damage, assembles into large surveillance complexes (BASC, BRCA1-A) to coordinate repair machinery, protects stalled replication forks from degradation, regulates transcription (co-activating p53 targets, interacting with RNA pol II, autoregulating its own promoter), maintains inactive X-chromosome XIST RNA localization, controls centrosome duplication, regulates ferroptosis via VDAC3/GPX4 transcription, and interfaces with the Fanconi anemia pathway through FANCD2 colocalization.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BRCA1 is a multifunctional tumor suppressor that orchestrates genome integrity through DNA double-strand break repair by homologous recombination, cell cycle checkpoint control, centrosome regulation, and transcriptional programs governing ferroptosis susceptibility, X-chromosome inactivation, and DNA methylation. The BRCA1–BARD1 heterodimer functions as a RING-type E3 ubiquitin ligase that ubiquitylates nucleosomal H2A at K13/K15 to promote homologous recombination over non-homologous end joining, with a cryo-EM structure revealing how BARD1 ankyrin-repeat and BRCT domains anchor the complex on nucleosomes and orient E2-mediated ubiquitin transfer [PMID:34321665, PMID:10549283]. BRCA1 is phosphorylated by ATM and ATR kinases at DNA damage sites, assembles into distinct nuclear complexes—including the BRCA1-A complex (RAP80/Abraxas/MERIT40/BRE/BRCC36) for damage-site retention and the BRCA1–CtIP complex for DNA end resection—and antagonizes 53BP1/RIF1 to permit resection in S/G2 phase [PMID:11114888, PMID:17643121, PMID:23486525]. Beyond repair, BRCA1 regulates transcription by binding the promoters of DNMT1, SIRT1, and GPX4, co-activates p53-dependent targets, represses estrogen receptor-α via mono-ubiquitination, maintains XIST RNA on the inactive X chromosome, and controls centrosome duplication through γ-tubulin binding [PMID:9582019, PMID:12419249, PMID:12214252, PMID:38552003].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing BRCA1 as a transcriptional co-activator: the discovery that BRCA1 physically binds p53 and co-activates p21 and bax promoters linked BRCA1 to transcription-coupled tumor suppression.\",\n      \"evidence\": \"Co-IP, in vitro binding, and reporter assays with tumor-derived BRCA1 mutants in human cells\",\n      \"pmids\": [\"9582019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether co-activation is direct or mediated through bridging factors\", \"Structural basis of the BRCA1–p53 interface\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defining the caretaker function: BRCA1-deficient ES cells showed impaired homologous recombination and increased non-homologous repair, establishing BRCA1 as a key determinant of DSB repair pathway choice.\",\n      \"evidence\": \"Brca1-knockout mouse ES cells with chromosomal DSB repair assays measuring HR vs. NHEJ frequencies\",\n      \"pmids\": [\"10549283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which BRCA1 promotes HR was unknown\", \"Identity of downstream effectors at the break site\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placing BRCA1 in the DNA damage signaling cascade: ATR was shown to directly phosphorylate BRCA1 at multiple sites in response to replication stress, identifying BRCA1 as a downstream effector of checkpoint kinases.\",\n      \"evidence\": \"In vitro kinase assay with site-directed mutagenesis and dominant-negative ATR, immunofluorescence co-localization at stalled forks\",\n      \"pmids\": [\"11114888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of individual phosphorylation events\", \"Relative contributions of ATM vs. ATR phosphorylation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Expanding BRCA1 beyond DNA repair: BRCA1 was found to localize to the inactive X chromosome, associate with XIST RNA, and maintain Xi silencing, revealing an epigenetic regulatory role.\",\n      \"evidence\": \"Immunofluorescence co-localization, ChIP for XIST RNA, GFP Xi-reporter assay with BRCA1 reconstitution\",\n      \"pmids\": [\"12419249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which BRCA1 stabilizes XIST RNA on Xi\", \"Whether this function is independent of E3 ligase activity\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linking BRCA1 to centrosome control: BRCA1 was shown to localize to centrosomes, bind γ-tubulin, and restrain centrosome duplication, connecting BRCA1 loss to chromosomal instability through a mitotic mechanism.\",\n      \"evidence\": \"Immunofluorescence localization, Co-IP with γ-tubulin, centrosome amplification in Brca1-KO mouse cells\",\n      \"pmids\": [\"12214252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate identity for BRCA1-dependent ubiquitination at centrosomes\", \"Whether centrosome and HR functions are separable in tumorigenesis\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dissecting domain requirements for damage-site recruitment: the RING and BRCT domains were shown to cooperate for IR-induced foci formation, and cancer-associated BRCT mutations abolished recruitment, explaining the functional impact of clinical variants.\",\n      \"evidence\": \"YFP-tagged domain constructs in MCF-7 cells with IR-induced foci assay and cancer mutation analysis\",\n      \"pmids\": [\"15569676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of BRCT-binding partner at foci (later shown to include phospho-Abraxas)\", \"Whether RING E3 activity is required at foci\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying a non-repair ubiquitin ligase substrate: BRCA1 was shown to ubiquitinate topoisomerase IIα in S phase, enhancing decatenation activity and revealing a role in resolving sister chromatid intertwining before mitosis.\",\n      \"evidence\": \"Co-IP, in vitro decatenation and ubiquitination assays, lagging chromosomes in BRCA1-deficient cells\",\n      \"pmids\": [\"15965487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin chain type on topoisomerase IIα\", \"In vivo confirmation of decatenation defect contribution to tumorigenesis\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defining the BRCA1-A complex architecture: Abraxas/CCDC98 was identified as the bridge between RAP80 and BRCA1, required for damage-induced BRCA1 foci and G2/M checkpoint activation, providing the first scaffold model for BRCA1 recruitment via ubiquitin signaling.\",\n      \"evidence\": \"Co-IP, RNAi knockdown, immunofluorescence foci and G2/M checkpoint assays\",\n      \"pmids\": [\"17643121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the Abraxas–BRCA1 BRCT interaction\", \"Whether complex composition varies by damage type\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Completing the BRCA1-A complex: MERIT40 was shown to stabilize the five-subunit complex through direct binding to BRE, and its depletion phenocopied BRCA1 depletion for damage-site retention and checkpoint function.\",\n      \"evidence\": \"Co-IP, RNAi knockdown, foci and checkpoint assays in human cells\",\n      \"pmids\": [\"19261748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the intact BRCA1-A complex\", \"Whether MERIT40 has functions independent of BRCA1\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying a negative regulator of BRCA1 E3 activity: BAP1 was shown to compete with BRCA1 for BARD1 binding and inhibit BRCA1/BARD1 ubiquitin ligase activity through both catalytic and non-catalytic mechanisms, establishing a regulatory axis for BRCA1 function.\",\n      \"evidence\": \"SPR, in vitro ubiquitination assay, catalytic mutant C91S, shRNA knockdown\",\n      \"pmids\": [\"19117993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological context of BAP1-mediated BRCA1 inhibition\", \"Whether BAP1 deubiquitinates BRCA1 substrates directly\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linking BRCA1 E3 activity to ER-α repression: BRCA1 was shown to mono-ubiquitinate ER-α at K302 via its RING domain, blocking p300-mediated acetylation, thereby repressing ER-α transcriptional activity—a mechanism abrogated by cancer-associated RING mutations.\",\n      \"evidence\": \"In vitro ubiquitination and acetylation assays with RING mutants I26A and C61G, Co-IP\",\n      \"pmids\": [\"19887647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo validation of K302 mono-ubiquitination\", \"Whether this repression operates constitutively or only in specific hormonal contexts\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealing BRCA1 transcriptional autoregulation: BRCA1 assembles with E2F-1 and RB at its own promoter to repress transcription, and genotoxic stress releases BRCA1 from this promoter, creating a feed-forward loop for damage-induced BRCA1 upregulation.\",\n      \"evidence\": \"Tandem ChIP, RNAi, overexpression, and reporter assays in human cells\",\n      \"pmids\": [\"20068145\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinetics of autoregulatory loop during physiological damage responses\", \"Whether E2F-1/RB complex formation is cell-type dependent\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining the molecular antagonism governing repair pathway choice: RIF1 was shown to counteract BRCA1-mediated end resection via 53BP1 phosphorylation in G1, while BRCA1 displaces RIF1 in S/G2, establishing the cell-cycle-dependent toggle between HR and NHEJ.\",\n      \"evidence\": \"RNAi epistasis, resection assays, immunofluorescence foci analysis across cell cycle phases\",\n      \"pmids\": [\"23486525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact mechanism by which BRCA1 evicts RIF1 from breaks\", \"Role of BRCA1 ubiquitin ligase activity in this antagonism\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Solving the structural basis of BRCA1-BARD1 nucleosome ubiquitylation: the cryo-EM structure showed how BARD1 recognizes H2A-ubiquitin at K13/K15 and positions the RING-E2 module for C-terminal H2A ubiquitylation, explaining how monoubiquitin recognition prevents polyubiquitin chains.\",\n      \"evidence\": \"Cryo-EM structure of BRCA1-BARD1 on nucleosome with functional ubiquitylation validation\",\n      \"pmids\": [\"34321665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How downstream readers interpret BRCA1-deposited H2A ubiquitin marks in vivo\", \"Structure of BRCA1-BARD1 engaged with CtIP or PALB2\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying a post-translational switch for BRCA1-BARD1 stability: SIRT2 deacetylates BARD1 RING domain lysines to promote BRCA1-BARD1 heterodimerization, nuclear retention, and HR efficiency, adding an acetylation-dependent regulatory layer.\",\n      \"evidence\": \"Co-IP, in vitro deacetylation assay, RNAi, foci and HR assays\",\n      \"pmids\": [\"33789098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the acetyltransferase opposing SIRT2\", \"Whether SIRT2 regulation is damage-inducible\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connecting BRCA1 to ferroptosis regulation: BRCA1 was shown to transcriptionally activate GPX4 and VDAC3, and its deficiency differentially sensitizes cells to GPX4 inhibitor-induced ferroptosis while conferring resistance to erastin, revealing a vulnerability exploitable with combined PARP/GPX4 inhibition.\",\n      \"evidence\": \"ChIP, gene expression analysis, BRCA1-KO cells, ferroptosis assays, xenograft models\",\n      \"pmids\": [\"38552003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ferroptosis sensitivity contributes to BRCA1-associated tumor suppression in vivo\", \"Mechanism linking BRCA1 to NCOA4-mediated ferritinophagy\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of BRCA1 complexes with CtIP and PALB2/BRCA2 on chromatin, the in vivo significance of individual BRCA1 phosphorylation sites for pathway choice, and how BRCA1's E3 ligase, transcriptional, and centrosomal functions are coordinately regulated during tumorigenesis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of BRCA1–CtIP or BRCA1–PALB2 complexes on DNA substrates\", \"Relative contribution of ligase-dependent vs. ligase-independent functions to tumor suppression not genetically dissected in human systems\", \"Mechanism integrating BRCA1 transcriptional targets (GPX4, SIRT1, DNMT1) with its DNA repair role\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 4, 8, 12, 13]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 9, 11, 14, 22, 24]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 5, 6, 7, 9, 15]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [4, 9, 10]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 4, 5, 6, 7, 8, 13]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 7, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 9, 11, 14, 22, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [9, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"complexes\": [\n      \"BRCA1-BARD1 E3 ubiquitin ligase\",\n      \"BRCA1-A complex (RAP80/Abraxas/MERIT40/BRE/BRCC36)\",\n      \"BRCA1-CtIP complex\"\n    ],\n    \"partners\": [\n      \"BARD1\",\n      \"TP53\",\n      \"RAP80\",\n      \"ABRAXAS1\",\n      \"MERIT40\",\n      \"CTIP\",\n      \"BAP1\",\n      \"TOP2A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"BRCA1 is a nuclear tumor suppressor that functions as a RING-type E3 ubiquitin ligase and central coordinator of the DNA damage response, homologous recombination repair, replication fork protection, and transcriptional regulation. BRCA1 heterodimerizes with BARD1 through its RING domain to ubiquitinate nucleosomal H2A, with substrate specificity determined by BARD1 recognition of DSB-specific monoubiquitin marks on H2A K13/K15 [PMID:34321665]; it is phosphorylated by ATM and ATR kinases at SQ/TQ clusters following DNA damage, which is required for radiation resistance [PMID:10550055, PMID:11114888]. BRCA1 promotes homologous recombination by interacting with RAD51, antagonizing 53BP1/RIF1-mediated end-protection to favor DNA end resection in S/G2 phase, and protecting stalled replication forks from degradation in an epistatic pathway with FANCD2 and RAD51 [PMID:9008167, PMID:10549283, PMID:20453858, PMID:22789542]. Germline loss-of-function mutations in BRCA1 cause hereditary breast and ovarian cancer susceptibility [PMID:7545954].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Before the gene was cloned, linkage analysis established that a breast cancer susceptibility locus resided on chromosome 17q21, defining the target for positional cloning.\",\n      \"evidence\": \"Genetic linkage (LOD score) with RFLP markers in early-onset breast cancer families\",\n      \"pmids\": [\"2270482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene identity unknown\", \"No protein or functional information\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Positional cloning identified BRCA1 as an 1863-amino-acid protein harboring a zinc-finger domain, with frameshift, nonsense, and missense mutations segregating in familial breast/ovarian cancer kindreds, establishing it as a tumor suppressor gene.\",\n      \"evidence\": \"Positional cloning with mutation sequencing and linkage analysis in affected families\",\n      \"pmids\": [\"7545954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical activity unknown\", \"Cellular function uncharacterized\", \"No structural data\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that BRCA1 colocalizes and physically interacts with RAD51 in S-phase nuclear foci and on meiotic chromosomes, and that DNA damage triggers BRCA1 hyperphosphorylation and redistribution to PCNA-positive replication structures, established BRCA1 as a participant in DNA repair and replication checkpoint responses.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro binding, immunofluorescence, phosphorylation shift assays in mitotic and meiotic cells\",\n      \"pmids\": [\"9008167\", \"9267023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic activity of BRCA1 unknown\", \"Upstream kinase not identified\", \"Mechanism of RAD51 cooperation unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"BRCA1 was shown to bind p53 and co-activate p53-dependent transcription from p21 and bax promoters, with cancer-derived mutants defective in this activity, revealing a transcriptional co-activator function linked to tumor suppression.\",\n      \"evidence\": \"Co-IP, GST pulldown, transcriptional reporter assays, domain mapping\",\n      \"pmids\": [\"9582019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect transcriptional mechanism unclear\", \"Genome-wide transcriptional targets unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Three key mechanistic advances established BRCA1's enzymatic identity and upstream regulation: the RING finger was shown to confer E2-dependent E3 ubiquitin ligase activity; ATM was identified as the kinase that phosphorylates BRCA1 at SQ clusters after ionizing radiation (required for radiation resistance); and Brca1-null ES cells were proven defective in homologous recombination repair of DSBs.\",\n      \"evidence\": \"In vitro ubiquitination with RING mutagenesis; in vitro kinase assay with ATM plus complementation rescue; DSB repair frequency assay in Brca1-knockout ES cells\",\n      \"pmids\": [\"10500182\", \"10550055\", \"10549283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ubiquitin substrates unidentified\", \"How E3 activity relates to HR unclear\", \"BARD1 contribution to E3 activity not yet dissected\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"BRCA1 was found to organize a large nuclear surveillance complex (BASC) containing mismatch repair, BLM helicase, MRN complex, ATM, and RFC, and ATR was identified as a second damage-responsive kinase directly phosphorylating BRCA1 at Ser1423, positioning BRCA1 as a central scaffold integrating multiple repair and checkpoint pathways.\",\n      \"evidence\": \"IP-mass spectrometry, co-IP, colocalization; in vitro kinase assay with dominant-negative ATR and phospho-specific antibodies\",\n      \"pmids\": [\"10783165\", \"11114888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of BASC unknown\", \"Which ATR phosphosites are functionally essential beyond Ser1423 unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Monoubiquitinated FANCD2 was shown to colocalize with BRCA1 at damage-induced foci, linking the Fanconi anemia pathway to BRCA1-dependent DNA repair and establishing a functional convergence of these tumor suppressor networks.\",\n      \"evidence\": \"Co-IP, immunofluorescence colocalization, monoubiquitination shift assay\",\n      \"pmids\": [\"11239454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between BRCA1 and FANCD2 not demonstrated at that time\", \"Mechanistic basis of functional epistasis unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"BRCA1 was found to colocalize with the inactive X chromosome, associate with XIST RNA, and be required for maintenance of XIST RNA concentration and X-linked gene silencing, revealing an unexpected role in epigenetic chromosome regulation beyond DNA repair.\",\n      \"evidence\": \"ChIP for XIST RNA association, immunofluorescence, reconstitution in BRCA1-deficient cells, GFP reporter assay\",\n      \"pmids\": [\"12419249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether XIST association is direct RNA binding or indirect via chromatin\", \"Relevance to tumor suppression not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Multiple studies expanded BRCA1's functional repertoire: BRCA1 ubiquitinates topoisomerase IIα to stimulate decatenation activity and ensure chromosome segregation; RING and BRCT domains cooperate for damage-induced foci recruitment; and CRM1-dependent nuclear export of BRCA1 after irradiation requires p53.\",\n      \"evidence\": \"Co-IP/ubiquitination/decatenation assays; YFP domain mapping in irradiated cells; subcellular fractionation with CRM1 inhibitor and p53 perturbation\",\n      \"pmids\": [\"15965487\", \"15569676\", \"15087457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of topoisomerase IIα ubiquitination for tumor suppression\", \"Structural basis of RING-BRCT cooperation unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The upstream chromatin signaling cascade recruiting BRCA1 to DSBs was defined: RNF8 ubiquitylates H2A/H2AX at breaks via MDC1, and the adaptor Abraxas/CCDC98 bridges RAP80 to BRCA1 for focal accumulation and G2/M checkpoint activation, establishing the BRCA1-A complex architecture.\",\n      \"evidence\": \"Co-IP, in vitro ubiquitination, siRNA knockdown, checkpoint assays, X-ray crystallography of RNF8 FHA domain\",\n      \"pmids\": [\"17643121\", \"18001824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BRCA1-A complex is disassembled after repair\", \"Relative contributions of multiple BRCA1 subcomplexes (A, B, C) to repair not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"BAP1 deubiquitinase was shown to bind the BARD1 RING domain via SPR, competing with BRCA1 heterodimerization and inhibiting BRCA1/BARD1 autoubiquitination through both enzymatic and steric mechanisms; separately, BRCA1 E3 ligase activity was shown to mono-ubiquitinate ERα, blocking p300-mediated acetylation and repressing ERα transcriptional activity.\",\n      \"evidence\": \"Surface plasmon resonance, in vitro ubiquitination/acetylation assays, catalytic mutant analysis, shRNA knockdown\",\n      \"pmids\": [\"19117993\", \"19887647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological regulation of BAP1–BARD1 competition in vivo\", \"Whether ERα ubiquitination occurs genome-wide or at specific loci\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"BRCA1 was shown to regulate its own promoter through an E2F1/RB-containing repressive complex (disrupted by genotoxic stress) and to maintain DNMT1 expression and genomic DNA methylation, extending its transcriptional regulatory roles to epigenomic maintenance and autoregulation.\",\n      \"evidence\": \"Tandem ChIP (Re-ChIP), promoter reporter assays, bisulfite sequencing in Brca1-mutant mouse models\",\n      \"pmids\": [\"20068145\", \"20820192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo significance of autoregulatory loop for tumor suppression unclear\", \"DNMT1 regulation not validated beyond one lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two genetic epistasis studies resolved how BRCA1 governs DSB repair pathway choice and fork protection: loss of 53BP1 rescued HR and checkpoint defects of Brca1-deleted cells (but not Brca2-deleted), defining BRCA1 as antagonizing 53BP1-mediated end protection; separately, BRCA1 and FANCD2 were shown to protect stalled replication forks from degradation in an epistatic pathway with RAD51.\",\n      \"evidence\": \"Conditional knockout epistasis in mouse cells with HR/checkpoint/drug sensitivity assays; DNA fiber assay with siRNA knockdown and RAD51 rescue\",\n      \"pmids\": [\"20453858\", \"22789542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which BRCA1 displaces 53BP1 not known at this time\", \"Whether fork protection and HR functions are separable\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"RIF1 was identified as the 53BP1 effector antagonized by BRCA1: RIF1 blocks end resection in G1, and BRCA1 counteracts RIF1 accumulation at DSBs in S/G2, providing a cell-cycle-dependent mechanism for repair pathway choice between NHEJ and HR.\",\n      \"evidence\": \"siRNA epistasis, immunofluorescence foci, end resection assay, cell cycle fractionation\",\n      \"pmids\": [\"23486525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism of RIF1 displacement by BRCA1 not resolved\", \"How BRCA1 senses cell cycle phase at individual DSBs unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Neural progenitor-specific Brca1 deletion caused severe brain agenesis through p53-dependent apoptosis, while centrosomal/polarity defects were ATM-dependent but p53-independent, establishing that BRCA1 has genetically separable apoptotic and centrosomal functions in vivo.\",\n      \"evidence\": \"Conditional KO mouse genetics with p53 and ATM double-KO epistasis, histology, immunofluorescence\",\n      \"pmids\": [\"24639535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Centrosomal substrate of BRCA1 E3 ligase in neural progenitors unidentified\", \"Whether neural phenotype contributes to cancer predisposition unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cryo-EM structure of BRCA1-BARD1 on a nucleosome revealed how BARD1 recognizes DSB-specific H2A K13/K15 monoubiquitin marks and positions the RING-E2 module to ubiquitinate H2A/H2AX C-terminal tails, explaining chromatin recruitment specificity and substrate selectivity of the heterodimer; concurrently, SIRT2 was shown to deacetylate BARD1 RING lysines to promote BRCA1-BARD1 heterodimerization, stability, and nuclear retention.\",\n      \"evidence\": \"Cryo-EM structure determination with biochemical ubiquitination and mutagenesis; Co-IP, in vitro deacetylation, HR assay, nuclear fractionation\",\n      \"pmids\": [\"34321665\", \"33789098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length BRCA1-BARD1 structure not yet resolved\", \"In vivo dynamics of SIRT2-mediated BARD1 deacetylation during the cell cycle unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"BRCA1 was found to transcriptionally regulate VDAC3 and GPX4, positioning it as a dual regulator of ferroptosis: BRCA1 deficiency blocks VDAC3-dependent ferroptosis while sensitizing cells to GPX4 inhibitor-induced ferroptosis, synergizing with PARP inhibition in BRCA1-deficient cancers.\",\n      \"evidence\": \"CRISPR/siRNA knockdown, ChIP, ferroptosis assays, xenograft and patient-derived xenograft models\",\n      \"pmids\": [\"38552003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ferroptosis regulation is a primary tumor-suppressive function or secondary consequence of transcriptional dysregulation\", \"VDAC3/GPX4 regulation not independently replicated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full spectrum of physiological BRCA1-BARD1 ubiquitin substrates beyond H2A, the structural basis by which BRCA1 displaces 53BP1/RIF1 at DSBs during S/G2, whether BRCA1's diverse non-repair functions (X-inactivation, ferroptosis regulation, centrosome control) contribute independently to tumor suppression, and how BRCA1 coordinates its scaffolding, enzymatic, and transcriptional activities at a single damage site.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Comprehensive substrate identification for BRCA1-BARD1 E3 ligase lacking\", \"Structural mechanism of 53BP1/RIF1 antagonism unresolved\", \"Contribution of individual BRCA1 functions to tissue-specific tumorigenesis unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [5, 13, 17, 18, 31]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 13, 18, 31]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [11, 20, 21, 33]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [10, 16, 20, 21, 33]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [31]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [7, 14, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 3, 7, 27, 30, 31, 32]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [2, 11, 13, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [2, 3, 4, 6, 7, 8, 23, 24, 25, 31, 32]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [3, 24, 28]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [14, 15, 19, 23, 25, 35]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 16, 20, 21, 29, 33]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [11, 15, 31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 34]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 33, 35]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [3, 4, 8, 14, 15, 25]}\n    ],\n    \"complexes\": [\n      \"BRCA1-BARD1 heterodimer\",\n      \"BASC (BRCA1-associated genome surveillance complex)\",\n      \"BRCA1-A complex (RAP80/Abraxas/MERIT40/BRCC36/BRE)\"\n    ],\n    \"partners\": [\n      \"BARD1\",\n      \"RAD51\",\n      \"TP53\",\n      \"ABRAXAS1\",\n      \"RAP80\",\n      \"BAP1\",\n      \"FANCD2\",\n      \"RIF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}